UNIVERSITY OF MICHIGAN W.K. KELLOGG EYE CENTER

2015 ANNUAL REPORT

~ Our Purpose ~

To improve lives

through curing,

preventing, and

treating eye disease

30th Anniversary

TEAMWORK

INTEGRITY

INNOVATION

CARING

Eye on the FutureUniversity of Michigan Kellogg Eye Center Annual Report 2015

22214 177

Kellogg Celebrates 30th Anniversary

4 Event at the U-M Museum of Art Marks Milestone

6 Establishing the Qais A. Farjo, M.D., Memorial Lectureship

Vision Restoration and Research

7 Kellogg Hosts First Meeting of Argus II® Retinal Prosthesis System Investigators

9 Kellogg Scientists Brief Congress on Vision Research

10 New Clinical Research Center Offers More Trials

12 Kellogg Partners with U-M Biointerfaces Institute to Accelerate Therapeutic Advances

Advances in Education and Patient Care

15 Kellogg Faculty Develop Digital Learning Tools

16 Residents Push Forward Innovations and Research

18 Eye Care Goes Back to School

19 Eye Clinic Expands at the VA

Philanthropy in Support of Research

20 Kellogg Receives $3.5M Gift from the Jerome Jacobson Foundation

21 Updates on Glaucoma Research at Kellogg

Global Initiatives

22 Kellogg Hosts Third Annual International Night

24 Helping an Ethiopian Hospital Establish an Ophthalmology Residency Program

Front cover: David Antonetti, Ph.D.; Elizabeth Du, M.D.; an image of the Kellogg Eye Center; Denise John, M.D.; Tyson Kim, M.D., Ph.D.; an image of a 3D embryonic stem cell culture from the lab of Robin Ali, Ph.D.; and Courtney Dewey, O.D.

*This report covers the time period of July 1, 2014 through September 30, 2015.

For patient appointments, please call 734.763.8122.

Clinic phone numbers are online under “Patient Care” at www.kellogg.umich.edu

2

Front row: Raymond Douglas, M.D., Ph.D., Shahzad Mian, M.D., and Denise John, M.D. Back row: Alan Sugar, M.D., Michael Smith-Wheelock, M.D., Thomas Gardner, M.D., M.S., and Paul Lee, M.D., J.D.

Dear Friends,

This past fall, the University of Michigan Department of

Ophthalmology and Visual Sciences, founded in 1872, celebrat-

ed the 30th anniversary of the W.K. Kellogg Eye Center. The

construction of the Kellogg Tower in 1985 enabled our depart-

ment to unify offices, laboratories and clinical spaces that were

scattered across seven medical campus buildings. The opening

of the Brehm Tower in 2010 provided room for expansion and

the opportunity to work more closely with leading diabetes

researchers. These tremendous facilities have enabled our fac-

ulty, staff and trainees to work more effectively at shaping the

future of vision science and eye care. Within these buildings, it

is the teamwork and ingenuity of our people that have been the

hallmarks of research, education and patient care at Kellogg.

In this year’s Annual Report, you will have the opportunity

to learn about some of the new ideas in research that Kellogg

scientists are pursuing in collaboration with colleagues from

around the University. For example, among our new initiatives

is a joint project with investigators at the U-M Biointerfaces

Institute. This collaboration has taken shape with three projects

aimed at exploring novel methods of diagnosing types of ocular

tumors and new treatments for diabetic retinopathy and macular

degeneration.

The new Kellogg Clinical Trials Center (KCRC), which

opened in June 2015, provides dedicated space at Kellogg for

our investigators to conduct clinical research in all areas of

ophthalmology. The KCRC team works with our faculty and

our volunteer patients to move clinical trials forward with the

goal of evaluating the effectiveness of new treatments. Some of

our current trials involve assessing innovative therapies for age-

related macular degeneration, investigating novel approaches

to treating cancer around the eye and examining a new therapy

for the treatment of dry eye disease.

The Chair’s Perspective

3

At Kellogg, we realize that sharing information and

experience means a faster path to improvement. As you may

recall from last year’s Annual Report, Kellogg retinal surgeons

performed the first four Argus II® Retinal Prosthesis System

(Argus II) implantations in the United States since FDA approv-

al. To improve the Argus II patient experience, Kellogg hosted

the first meeting of Argus II Investigators. Over 50 retinal sur-

geons, researchers and rehabilitation professionals from around

the world who have worked with the implant, met to discuss

and share approaches, surgical and rehabilitation techniques

and outcomes. Five additional implan-

tations have since been performed at

Kellogg. Worldwide, the Argus II has now

been implanted in over 130 patients in

29 centers in the United States, Europe

and the Middle East.

Expanding a commitment to global

initiatives, two of our faculty members

served as advisors in establishing a state-

of-the-art residency training program for

ophthalmologists at the St. Paul Hospital

Millennium Medical College in Addis

Ababa, Ethiopia. The program, one of

only four in the country, began training

its first six residents last year. We are

excited to work with our Ethiopian colleagues to develop the

program and an eye care center that will become a regional

center of excellence. We also welcomed Thomas Lietman, M.D.,

Director of the F. I. Proctor Foundation, as our Center for

International Ophthalmology’s third Scholar-in-Residence,

benefiting from his expertise in trachoma and other ocular

infectious diseases throughout the world.

Two of our faculty members have developed innovative

ways to make information and training more accessible.

Jonathan Trobe, M.D., Professor, authored The Eyes Have It,

an educational app for iOS and Android, cataloging 134 eye

conditions, 410 images, more than 40 narrated animations and

patient videos, six screening examination videos and an eye

anatomy review. Assistant Professor Elizabeth Du, M.D., has

developed a comprehensive four-week Coursera online class

Introduction to Cataract Surgery for residents and trainees

who will perform cataract surgery. The course, which is free

of charge and offered globally, has run twice with 545 people

in 131 different countries completing the instruction.

Among those at Kellogg honored for their achievements

this year was Devon Ghodasra, M.D., vitreo-retinal surgery

fellow, who was awarded the Raymond R. Margherio Award

for his research on vitreous cytokines. In addition, Thomas

W. Gardner, M.D., M.S., Professor, was awarded the Retina

Society Award of Merit in Retina Research honoring Charles

L. Schepens, which recognizes outstand-

ing national achievement in retina research.

Mark W. Johnson, M.D., Professor and

head of Kellogg’s Retina and Uveitis Service,

was elected to serve as the new president of

the Retina Society.

From developing new treatments and

educational innovations to cultivating leaders

in the field, the people of Kellogg have done

and continue to do much to advance the

visual sciences and the care of our patients.

In 2015, Kellogg had more than 163,000

patient visits and performed more than

7,600 surgical procedures. As our patient

volumes grow, we are more motivated than

ever to achieve our goal of improving lives through curing,

preventing, and treating eye disease.

We want to thank all who have contributed to our growth,

research and successes. You helped make the achievements

of the last year and the last 30 years possible. Together, we

are partners in solving eye disease and are excited and eager

to accomplish even more in the coming years.

Paul P. Lee, M.D., J.D.

F. Bruce Fralick Professor and

Chair, Ophthalmology and Visual Sciences

Director, W.K. Kellogg Eye Center

“Together, we are partners

in solving eye disease and

are excited and eager to

accomplish even more in

the coming years.” —Paul P. Lee, M.D., J.D.

1985 2015

PATIENT VISITS 36,852 163,232SURGERIES 1,825 7,681FACULTY 15 96RESEARCH FUNDING $0.9M $14M

30 Years of Service

Growing to better serve our patients and expanding our research to find new treatments to cure blinding eye diseases.

4

Last fall, Kellogg celebrated its 30th anniversary with an event

at the University of Michigan Museum of Art. Among our

many honored guests were Paul A. Sieving, M.D., Ph.D., former

faculty member and founder of Kellogg’s Center for Retinal and

Macular Degeneration and current Director of the National Eye

Institute at the National Institutes of Health; and Linh Nguyen,

chief operating officer of the W.K. Kellogg Foundation.

Paul R. Lichter, M.D., M.S., Founding Director of the

W.K. Kellogg Eye Center and former Chair of the Department

of Ophthalmology and Visual Sciences for 34 years, highlighted

the remarkable growth and change during the last three decades.

Mr. and Mrs. John R. Breen announced a $3.5M gift from

the Jerome Jacobson Foundation. “Jerome’s friends often heard

how Dr. Lichter, his longtime physician, assured him that with

proper management of his condition—through medication

and surgeries when necessary—he would have sight on the last

day of his life. And he did,” says Mr. Breen, co-trustee of the

Foundation.

Earlier in the day, at Kellogg’s Fall Reunion, Anand

Swaroop, Ph.D., former Kellogg faculty member and current

Chief of the Neurobiology-Neurodegeneration and Repair

Laboratory at the National Eye Institute, returned to give

the inaugural address of the Qais A. Farjo, M.D., Memorial

Lectureship.

For more information about these gifts, see pages 6 and 20.

KELLOGG CELEBRATES 30TH ANNIVERSARY

Marking an Important Milestone in our Eye Center’s Growth and History

Mr. and Mrs. Dan Kachnowski share a toast. Jerry May, Vice President of the U-M Office of Development, chats with Thomas Varbedian, M.D.

Mr. and Mrs. John Breen, Jerome Jacobson Foundation.

Aisha Faridi, Amjad Ahmad, M.D., John Arendshorst, M.D., Linda Katz, M.D., and Douglas Katz, M.D., at the 30th anniversary event.

5

Paul Lichter, M.D., M.S., Paul Lee, M.D., J.D., and Linh Nguyen, COO, W.K. Kellogg Foundation.

James Woolliscroft, M.D., former Dean of the U-M Medical School, shares a moment with Michael Staebler, J.D.

30th Anniversary celebration at the University of Michigan Museum of Art.

“Our vision was for Kellogg to become

one of the finest eye centers in the

nation and that has been realized.

We now have the facilities and, more

importantly, the people to shape the

future of eye care and vision science.” — Paul R. Lichter, M.D., M.S.

Paul R. Lichter, M.D., M.S., at the podium.

6

Anand Swaroop, Ph.D., and Paul A. Sieving, M.D., Ph.D., join in the celebration.

Anastas Farjo, M.D., Anand Swaroop, Ph.D., Muno Farjo, M.D., Rand Farjo, M.D., Deena Farjo, Rafid Farjo and Reem Farjo.

Kellogg faculty and alumni gather at Fall Reunion Day to celebrate the introduction of the first Qais A. Farjo, M.D., Memorial Lecture.

THE QAIS A. FARJO, M.D., MEMORIAL LECTURESHIP

A Fitting Tribute to One of Our Department’s Most Beloved Alumni

The Qais A. Farjo, M.D., Memorial Lectureship was created through the gen-erosity of those who were touched by Dr. Farjo’s life and highlights his broad exper-

tise in research, clinical care and education. The lectureship will enable the Department to host speakers who will share advances in their specialties, from translational research to collaborative care, to innovative surgical techniques. A remarkable physician, surgeon, researcher and mentor, Dr. Farjo completed his medical degree, residency and fellow-ship at the University of Michigan before joining the faculty of the Department of Ophthalmology and Visual Sciences. Dr. Farjo is known for his contributions to basic research through his characterization of the NRL gene, now known as a master transcription factor governing photoreceptor cell fate during development. He also served as medical director of the Michigan Eye-Bank. Dr. Farjo died in February 2014 after fighting a courageous battle against cancer. The inaugural address was given by Anand Swaroop, Ph.D., former faculty member and Chief of the Neurobiology-Neurodegeneration and Repair Laboratory at the National Eye Institute, during the 21st Annual Fall Reunion Day.

7

Collective Experience Draws Specialists from Top Tier Institutions Around the World

In 2014, Kellogg retinal surgeons performed the first four

Argus II® Retinal Prosthesis System (Argus II) implantations

in the United States of an artificial retinal sensing device, or

“bionic eye,” which was approved in 2013 by the U.S. Food

and Drug Administration. Five additional

implantations have since been performed at

Kellogg. The device is intended for patients

with retinitis pigmentosa, a degenerative and

blinding eye disease. Worldwide, Argus II has

now been implanted in over 130 patients in

29 centers in the United States, Europe and

the Middle East.

In 2015, Kellogg hosted the first meeting

of Argus II Investigators, providing an oppor-

tunity for over 50 retinal surgeons, researchers and rehabilita-

tion professionals to sit together in one room to discuss surgical

techniques and outcomes.

“This was a significant event, the first of its kind, marking

a critical juncture for all of us to share experiences, highlight

challenges and reflect on what we’ve learned,” says K. Thiran

Jayasundera, M.D., Assistant Professor. “The need for open

communication is central—not just between different segments

of people in one institution, but across institutions—so that

as a group we can refine this process that will ultimately benefit

our patients.”

Initial experiences with the Argus II implant have delivered

favorable results, as well as new challenges. The event focused

on four areas of optimization—patient

selection, device programming, visual

rehabilitation and surgical technique.

“The meeting covered the entire process

of an Argus II treatment, which starts with

screening patients to find the right fit to

ensure that each patient has realistic expec-

tations and the correct motivations,” says

Byron L. Lam, M.D., Professor and Robert

Z. & Nancy J. Green Chair in Ophthalmol-

ogy at the Bascom Palmer Eye Institute. “There were produc-

tive technical discussions particularly about how to make the

implantation more successful and how to avoid some of the

adverse events that can occur.”

Kellogg hosts the first worldwide meeting of Argus II investigators.

“This was a significant event, the first

of its kind, marking a critical juncture

for all of us to share experiences,

highlight challenges and reflect on

what we’ve learned.”

— K. Thiran Jayasundera, M.D.

WORLDWIDE NETWORK OF ARGUS II® INVESTIGATORS JOIN FORCES

Robert J. Greenberg, M.D., Ph.D., Chairman of Second

Sight Medical Products, the device manufacturer, noted that the

meeting marks an important milestone. “This is the first time

that a critical mass from around the world is together sharing

their great experiences with the technology,” says Dr. Greenberg.

“There is a real sense of excitement.”

Moving forward, Dr. Greenberg expects that the external

system for the next generation Argus II will be available in some

markets worldwide beginning in late 2016.

Selecting the right patient

Genetic counselor and Assistant Research Scientist Kari E.

Branham, M.S., CGC, works with patients during the screening

process to see if they are candidates for the Argus II implant.

“A great deal of effort must be put into the patient selection

process. The process from pre-op to rehabilitation is rigorous

with the requirement of a series of visits,” says Ms. Branham.

“Completing a comprehensive evaluation by an occupational

therapist before surgery helps identify learning styles, cognitive

and physical impairments, psychological concerns, and to

continue conversations with patients about setting reasonable

goals, managing expectations and staying motivated throughout

the long rehabilitation process.”

Fine tuning the device programming

Electrophysiologist and Assistant Professor Naheed W. Khan,

Ph.D., assesses outcomes and works with device programming

at Kellogg. “If the patient is to perceive visual signals, the device

must be programmed correctly and adjusted over time,” says

Dr. Khan. “Device programming requires two to three sessions,

which can be arduous for the patient, but this step can deter-

mine the quality of visual performance and whether the patient

can use the device successfully.”

Optimizing visual rehabilitation

In visual rehabilitation, therapists help patients learn how to

interpret the new kinds of visual signals they perceive and then

incorporate them into daily activities. “To use the device to its

fullest, patients must complete a two-pronged rehabilitation

program: in-clinic rehabilitation with an occupational or low

vision therapist and community rehabilitation with an orien-

tation and mobility specialist,” says occupational therapist

Ashley Howson, M.S., OTR/L. “As part of the rehabilitation

process, therapists provide training and guided practice to help

the patient learn how to use the device to increase independence

and quality of life with meaningful activities such as identifying

where a loved one is standing, sorting laundry or detecting lines

in a crosswalk.”

Evaluating surgical outcomes

Along with selecting the right patient, fine tuning the device

and optimizing visual rehabilitation, Dr. Jayasundera reflected

on some of the surgical variables that could improve patient

outcomes. “Based on a very small sample size, it appears that

younger patients may have better visual function after surgery,

possibly due to a healthier residual inner retina,” he explains.

“We also concluded that we may not need to exclude patients

with staphyloma, an abnormal protrusion of the uveal tissue via

a weakness in the eyeball, but rather should adapt our surgical

technique. Moreover, there is a need to develop surgical strate-

gies to avoid hypotony, an intraocular pressure of 5 mm Hg or

less, and conjunctival erosion.”

Proposed modifications to the device include new glasses

and a vector processing unit with increased comfort, longer

battery life, improved ease of use, custom camera, improved

telemetry, faster processing and new filters.

THE ARGUS USERS' SUPPORT GROUP

In 2015, the Kellogg Argus II team hosted the First Argus II® Retinal Prosthesis System Users' Support Group. The meeting provided a platform for our Argus II users to share their experiences with the device with one another, the Kellogg Argus II team, and engineers at Second Sight, the device manufacturer.

Donna Chapman, Linda Schulte and Mary Hawkins at the first Argus II® Retinal Prosthesis System Users' Support

Group held at Kellogg.

9

Rajesh C. Rao, M.D., Assistant Professor, and postdoctoral

fellow and incoming resident Jason Matthew-Lewis Miller,

M.D., Ph.D., were among 22 scientists selected to update

members of the U.S. Congress on ophthalmic science last fall

by the National Alliance for Eye and

Vision Research (NAEVR) Emerging

Vision Scientists Program, a coalition of

55 professional, consumer and industry

organizations involved in eye care. Drs.

Rao and Miller presented summaries

of their research to Congressional staff,

attended a House hearing on vision

research and met with U.S. representa-

tives and senators to lobby for expanded

funding for the National Eye Institute.

“I am honored to represent young

vision scientists at Kellogg and across the country in our collec-

tive goal to highlight the importance of vision research in finding

new treatments and cures for blindness to our nation’s lawmakers,”

says Dr. Rao. “From gene therapy to stem cells to preci-

sion medicine, we have never been at a more promising time

in translating cutting-edge technologies to patient care for

diseases such as age-related macular degeneration, diabetic

retinopathy, inherited retinal degenerations

and eye cancers.”

Dr. Rao explains that there remains a great

deal of work to do. “As the largest supporters

of vision research, our lawmakers, through the

National Eye Institute, Departments of Defense

and Veterans Affairs, and other agencies, play

the most important role in finding new cures

for blindness,” says Dr. Rao. “We want to assist

them in budgeting for the future, since vision

loss from blinding eye diseases will worsen as

our population ages. I hope that our advocacy

will play a part in ensuring our nation’s future needs for our

most valued sense—vision—which allows us to read, walk,

drive, work, recognize faces and care for others.”

“I am honored to represent young vision

scientists at Kellogg and across the coun-

try in our collective goal to highlight the

importance of vision research in finding

new treatments and cures for blindness

to our nation’s lawmakers.”

—Rajesh C. Rao, M.D.

Rajesh Rao, M.D., (left) and Jason Miller, M.D., Ph.D., update members of the United States Congress.

KELLOGG SCIENTISTS SELECTED

BY THE NATIONAL ALLIANCE FOR

EYE AND VISION RESEARCH TO

BRIEF CONGRESS

10

In an effort to offer more clinical trials to patients, the Eye

Center recently opened its Kellogg Clinical Research Center

(KCRC)—5,100-square-feet of dedicated space for investiga-

tors who conduct clinical research with resources to support

patient-oriented research studies in the specialties of retina,

cornea, glaucoma and pediatrics. Ocular oncology, oculo-

plastics and telemedicine projects are also included. Having

dedicated space for clinical trials frees the ophthalmology

clinics from the complicated process of registering and

examining clinical trial patients.

Grant M. Comer, M.D., M.S., Assistant Professor, leads

the eight-person KCRC team, who work with Kellogg faculty

and volunteer patients to move clinical trials forward with

the goal of finding new treatments of high impact.

“We have seen tremendous progress in our ability to

operate a wider range of clinical trials over the past year,” says

Dr. Comer. “From the addition of personnel with expertise in

clinical trial operations to the opening of the research space in

June, the KCRC, faculty scientists and our research volunteers

are already exploring the next generation of treatment options

available to our patients.”

Our current trials include a study to improve the treatment

of wet age-related macular degeneration, the investigation of a

new drug to treat cancer around the eye and the examination

of a supplement to treat dry eye disease.

The following stories highlight a few of our current trials.

For a full list, visit: www.kellogg.umich.edu/research/open_

clinicaltrials.html

KELLOGG EXPLORES INVESTIGATIVE NEW TREATMENT FOR WET MACULAR DEGENERATION

Wet age-related macular de-

generation (AMD) is caused

by the growth of abnormal

blood vessels beneath the

macula, the part of the retina

that provides detailed, central

vision. These blood vessels

are fragile and tend to hemor-

rhage or leak fluid, resulting

in the formation of scar tissue

that can lead to permanent vision loss. Currently, the best treat-

ment for wet AMD is injections of vascular endothelial growth

factor (VEGF) inhibitors, which have been shown to improve

vision rather than simply slowing the rate of vision loss. For

patients to reap the benefits of these injections, however, they

usually have to be done repeatedly.

Grant M. Comer, M.D., M.S., Assistant Professor, is

NEW CLINICAL TRIALS CENTER OPENS THE DOOR FOR MORE STUDIES

Grant Comer, M.D., M.S., examines Gwendolyn Rosier, a patient in his trial on treatments for proliferative diabetic retinopathy, in the new Kellogg Clinical Research Center.

11

exploring a potential new treatment—encapsulated cell therapy

or ECT—that he hopes will replace these injections. The NT-

503 ECT implant, about the size of a grain of rice, is surgically

placed into the eye under local anesthesia and contains tiny

capsules of cells that continuously release VEGF inhibitors to

the back of the eye to treat wet AMD.

Through this randomized study, Dr. Comer and his team

will compare treatment with the NT-503 ECT implant to the

routine injections patients receive for wet AMD. “Clinicians

have been searching for ways to reduce the frequency of

injections into the back of the eye that are often required for

wet AMD,” says Dr. Comer. “This clinical trial will allow us

to explore the safety and effectiveness of this new way of

delivering these medications.”

The study is currently enrolling patients with the goal of

six at Kellogg and 90 worldwide. Participation in this study

is for two years. Eligible patients must have active, wet AMD

and have had a good response to previous injections of a VEGF

inhibitor drug (Avastin, Lucentis or Eylea). Kellogg is one of

approximately 36 international sites participating in this study,

which is sponsored by Neurotech Pharmaceuticals, Inc. For

more information, contact clinical research coordinator Pamela

Campbell, COT, CCRP, at pamtitus@med.umich.edu.

KELLOGG INVESTIGATES NEW DRUG TO TREAT CANCER AROUND THE EYE

Vismodegib is a new drug

recently approved by the

U.S. Food and Drug Admin-

istration for treatment of

advanced or aggressive basal

cell carcinoma (BCCA), the

most common type of eye

cancer, affecting approxi-

mately 750,000 people in the

United States every year.

Oculoplastic surgeon Alon Kahana, M.D., Ph.D., Associ-

ate Professor, is leading a research team that aims to determine

whether vismodegib can be used to preserve vital tissues around

the eye as well as visual function in patients with BCCA. The

team also will perform basic and translational research on the

response of cancer tissue to the drug. The clinical trial, termed

VISORB (for VISmodegib for ORbital and periocular Basal cell

carcinoma), was awarded a competitive research grant from

Genentech, Inc., the manufacturer of vismodegib, which also

will provide the drug for the trial. Additional funding was

obtained from the U-M Head and Neck Oncology Program,

Kellogg and the U-M Comprehensive Cancer Center. The goal

of the trial is to test whether this new drug will lead to improved

ophthalmic outcomes in patients suffering from BCCA around

the eye and to identify markers for tumor response.

“Advanced basal cell carcinoma is commonly found around

the eye and can be disfiguring and blinding,” says Dr. Kahana.

“A clinical trial is needed to study how this innovative new drug

can be used to treat this cancer while preserving visual function.

Given how common basal cell carcinoma is, and its potential

impact on vision, I’m pleased that such an important trial will

be based at Kellogg and at U-M.”

Enrollment for this trial is open to patients with BCCA and

Kellogg plans to enter 50 patients over four years. Participation

in the study is for one year after initiation of the drug treatment.

For more information, contact clinical research coordinator

Sonal Trivedi, M.S., CCRP, at strivedi@med.umich.edu.

KELLOGG EXPLORES SUPPLEMENTS AS TREATMENT FOR DRY EYE

Cornea specialist Roni M.

Shtein, M.D., M.S., Associ-

ate Professor, is leading the

Kellogg site of the Dry Eye

Assessment and Management,

or DREAM, trial in hopes

of finding a new treatment

option for a condition that

can cause severe ocular

pain, corneal scars and ulcers,

and loss of vision.

The DREAM study evaluates the safety and effectiveness

of omega-3 fatty acid supplements to treat the symptoms of

moderate to severe dry eye disease. These over-the-counter

nutritional supplements are currently used to treat high levels

of fat in the blood.

“Dry eye disease is extremely common and leads many

patients to seek care from their eye care professionals,” says

Dr. Shtein. “The DREAM study is the first major trial on dry

eye disease that is not funded by a pharmaceutical company.

We are excited to be a part of it.”

Participation in the study is for one year. Eligible patients

may extend their participation for an additional year. Dr. Shtein

and her team hope to enroll 50 patients here at Kellogg, with a

national goal of 600 patients. The trial is led by the University

of Pennsylvania and funded by the National Eye Institute, a

branch of the National Institutes of Health.

For more information, contact clinical research coordina-

tor Munira Hussain, M.S., COA, CCRP, at hussain@med.

umich.edu.

12

Kellogg scientists partnered with the U-M Biointerfaces

Institute, a group of interdisciplinary biomedical researchers, at

a recent two-day conference to address barriers to solving thera-

peutic challenges for patients with blinding eye diseases. The

B-EYE Biointerfaces Institute/Ophthalmology Challenge, a joint

initiative focused on how interactions in the life sciences, physi-

cal sciences and engineering can accelerate the development of

new drug delivery systems, was inaugurated at this conference.

Belinda Seto, Ph.D., Deputy Director of the National Eye

Institute, delivered the keynote address Vision Breakthroughs

Enabled by Multidisciplinary Approaches. The

event also included presentations by special-

ists in ophthalmology and biomedical sciences,

followed by breakout sessions where attendees

brainstormed ideas and concepts, identified

challenges, and designed next steps for collab-

orative research and seed fund proposals in the

categories of biomaterials and drug delivery,

microfluidics and sensors, cell and tissue engi-

neering, and nanotechnology.

Three Kellogg faculty members were awarded B-EYE grants

Hakan Demirci, M.D., Associate Professor and Director of

Ocular Oncology, was the recipient of a challenge grant for

his proposal In-vivo Biopsy of Intraocular Tumors by Physio-

chemical Photoacoustics. Dr. Demirci’s work seeks to aid in the

differential diagnosis of intraocular tumors such as choroidal

melanomas, hemangiomas and metastases. He is collaborating

with U-M Department of Radiology research investigator

Guan Xu, Ph.D., to develop an ocular imaging system, called

photoacoustic imaging, a non-invasive, low cost imaging

technology for structural and functional imaging.

David A. Antonetti, Ph.D., Professor, was the co-recipient

of a challenge grant for his project Sustained Drug Delivery

for Restoration of Blood Retinal Barrier in Macular Edema.

Dr. Antonetti will collaborate with Steven P. Schwendeman,

Ph.D., the Ara G. Paul Professor and Chair of the U-M Depart-

ment of Pharmaceutical Sciences, to develop drug delivery de-

vices for novel drugs that target vessel permeability in the retina,

a problem in many leading vision-threatening diseases, including

diabetic retinopathy and age-related macular

degeneration.

“One of our major goals at Kellogg is to

translate our findings into better therapies for

our patients. Collaborations with groups such

as the U-M Biointerfaces Institute can provide

important avenues that allow us to turn our

discoveries into novel treatments for eye diseas-

es,” says Dr. Antonetti. “For example, we’ve

identified important signaling pathways and

are developing inhibitors to control these path-

ways. Interactions with faculty like Dr. Schwendeman will allow

us to develop the best ways to deliver these drugs to patients.”

Rajesh C. Rao, M.D., Assistant Professor, received a chal-

lenge grant for his proposal Direct Reprogramming of Fibro-

blasts into Photoreceptors by Defined Factors: A Novel Thera-

peutic Approach for Dry Age-Related Macular Degeneration,

A Common and Untreatable Cause of Blindness. Dr. Rao will

work with Kellogg postdoctoral fellow Qiang Li, M.D., Ph.D.;

U-M Department of Pathology research investigator Luis Villa

Diaz, Ph.D.; and Paul H. Krebsbach, D.D.S., Ph.D., the Roy H.

Roberts Professor of Dentistry, Professor of Biomedical Engi-

neering, and Chair of the Department of Biologic and Materials

Sciences and Division of Prosthodontics at the U-M School of

Dentistry. Dr. Rao will work with Dr. Krebsbach to reprogram

skin cells to retinal cells without going through an intermediate

embryonic stem cell stage.

“Collaborations with groups such

as the U-M Biointerfaces Institute

can provide important avenues that

allow us to turn our discoveries into

novel treatments for eye diseases.”

—David A. Antonetti, Ph.D.

KELLOGG SCIENTISTS JOIN FORCES WITH U-M BIOINTERFACES INSTITUTE

Collaboration Sparks Opportunities to Accelerate Bench to Bedside Discoveries

Hakan Demirci, M.D., David Antonetti, Ph.D., and Rajesh Rao, M.D.

13

KELLOGG FACULTY AWARDED R01 GRANTS

David A. Antonetti, Ph.D., Pro-

fessor, has received the renewal of

his NIH R01 grant Mechanisms

of Retinal Vascular Permeability

in Diabetes. Dr. Antonetti studies

the cellular mechanisms by which

endothelial cells, the cells that make

up blood vessels, proliferate and are

altered during diabetic retinopathy

and macular edema. Recent clinical

trials have demonstrated that target-

ing vascular endothelial growth factor (VEGF) can effectively

prevent progression of vision loss and, for some patients, restore

visual acuity. However, not all patients respond to anti-VEGF

therapies, which require repeated intraocular injections. There-

fore, understanding how VEGF prevents vessel alterations is

critical.

Dr. Antonetti also studies inflammatory factors that are

elevated in patients with diabetic retinopathy. Understanding the

mechanisms underlying the effects of growth and inflammatory

factors, as well as proteins such as occludin that are involved in

vessel permeability, is expected to provide new insight into the

nature of blood vessel growth and maturation. “My ultimate

goal is to identify new targets for therapeutic intervention that

are effective against growth factors and inflammatory cyto-

kines,” says Dr. Antonetti.

Bret A. Hughes, Ph.D., Professor,

has received the renewal of his NIH

R01 grant Ion Conductances in the

Retinal Pigment Epithelium. Dr.

Hughes’ overall goal is to under-

stand how ion channels in the cell

membranes of the retinal pigment

epithelium (RPE) operate to maintain

the salt and water balance of the

photoreceptor environment. Muta-

tions in several genes that encode ion

channels expressed in the RPE have been found to cause retinal

degeneration, underscoring the crucial role that these membrane

proteins play in maintaining retinal health and integrity.

Dr. Hughes hopes that further research on ion channels

in the RPE will identify additional ion channel genes that are

essential to keeping the photoreceptors healthy. “This research

is relevant as it will fill large gaps in our knowledge of how

the healthy RPE works to sustain the photoreceptors and

may also shed new light on what causes retinal degeneration,”

he says.

Thomas W. Gardner, M.D., M.S., Professor, and Steven F. Abcouwer,

Ph.D., Associate Professor, have

received the renewal of their NIH

R01 grant Regulation of Retinal Cell

Death in Diabetes. The ultimate goal

of their research is to develop treat-

ments that will prevent vision loss in

persons with diabetes. This project

focuses on how diabetes impacts

the retinal neurons that provide vi-

sion. Recently developed anti-VEGF

therapies can limit damage in many

patients with advanced diabetic

retinopathy. These treatments are

employed late in the disease process,

when blood vessels are affected, but

do not address the earlier damage

to the neurosensory retina caused

by diabetes.

Drs. Gardner and Abcouwer

are continuing their studies, which identify novel pathways that

cause dysfunction and death of these neurons, in the hope that

therapies intervening at earlier stages of diabetes will prevent

severe damage. The specific goals of this study are to define

the role of proteins called “mechanistic target of rapamycin

complexes” (mTORC) in retinal neuron function and survival,

and to define the ways in which diabetes affects these protein

complexes to cause diabetic retinopathy. “We hope that under-

standing the mechanisms underlying changes in these protein

complexes will enable development of therapies to prolong the

survival of retinal neurons and prevent the onset of sight-threat-

ening diabetic retinopathy,” says Dr. Gardner.

14

Automated Scalable Heat Shock Modification for Standard

Aquatic Housing Systems

Inventors: Alfonso Saera-Vila, Ph.D., Phillip E. Kish, Ph.D.,

and Alon Kahana, M.D., Ph.D.

Aquatic organisms are very useful for the experimental

study of human disorders. Changing the growth conditions

of aquatic model organisms, including water temperature and

pharmacologic exposure, is a very common research tool.

In order to improve the technology for changing tempera-

ture (i.e. “heat shock”) or drug delivery to aquatic colonies for

experimental and drug-screening purposes, Kellogg’s team of

inventors developed a parallel manifold system with continuous

water flow that reduces labor and improves reproducibility of

treatment conditions.

Mapping of Internal Features on En Face Imagery

Inventors: Lawrence E. Kagemann, Jr., Ph.D., (University

of Pittsburgh), Joel S. Schuman, M.D., FACS (University

of Pittsburgh), and Sayoko E. Moroi, M.D., Ph.D.

Minimally invasive glaucoma surgeries (MIGS) are a new

classification of glaucoma procedures designed to lower the

pressure inside the eye. A major assumption of surgical success

is that abnormal resistance resides in the trabecular network

and, once this resistance is bypassed, the outflow through

Schlemm’s canal and beyond is unimpeded. Outcomes, however,

are not predictable and these procedures are performed with

no prior knowledge of the morphology of the patient’s aqueous

humor outflow tract.

In order to better predict the outcome of MIGS procedures,

the team of inventors developed a system that will display

optical coherence tomography images that a surgeon can use

to select anatomical features, biomarkers and other features

of interest. The system can then translate the location of these

features to an en face image and generate a map used for surgi-

cal planning.

Magnetoelastic Actuator for Glaucoma Drainage Devices

Inventors: Yogesh B. Gianchandani, Ph.D. (U-M College of

Engineering), Venkatram Pepakayala, M.S.E. (U-M College of

Engineering), and Joshua D. Stein, M.D., M.S.

Glaucoma drainage devices (GDDs) divert aqueous humor

from the anterior chamber to an external reservoir, where a fi-

brous capsule forms about 4-6 weeks after surgery and regulates

flow. GDDs have been successful in controlling intraocular pres-

sure and preventing the worsening of glaucoma.

One issue with these devices has been the resistance to

aqueous flow through the GDDs across the fibrous capsule

around the end plate. To ease this resistance, the team invented

an enhancement to the GDDs using actuators with custom-

ized geometries and 3D curvatures. These actuators, which are

remotely excited to resonance with a magnetic field generated by

external coils, produce mechanical vibrations that can improve

aqueous flow, prevent adhesion of scar tissue to the implant and

facilitate removal of cells responsible for the development of

dense fibrous tissues around the implant. By limiting scar tissue

around the GDDs, the device can more effectively control the

intraocular pressure.

PATENTS FILED FOR INVENTIONS BY KELLOGG FACULTY

Alon Kahana, M.D., Ph.D., Sayoko Moroi, M.D., Ph.D., and Joshua Stein, M.D., M.S., all moved their inventions forward by filing for patents in 2015.

15

Elizabeth Du, M.D., has developed a Coursera online class for ophthalmologists.

KELLOGG BRINGS COURSERA ONLINE CLASS TO RESIDENTS WHO WILL PERFORM CATARACT SURGERY

Introduction to Cataract Surgery is Offered Globally, Free of Charge

Elizabeth Du, M.D., Assistant Professor, saw a need to make

learning the fundamentals of performing successful cataract

surgery more accessible to residents and trainees in the United

States and worldwide.

To meet this need, Dr. Du developed a comprehensive

four-week Coursera online class Introduction to

Cataract Surgery. The course has run twice—in

October 2014 and February 2015—with 545

people in 131 different countries completing the

instruction and 2,610 people visiting the course

site and watching at least a lecture.

“We wanted to create a course to teach

the basics of cataract surgery on the Coursera

platform for a number of reasons,” says Dr. Du.

“First, we thought it would benefit our residents

and other trainees as they prepare to become

cataract surgeons to have a comprehensive

course delivered in a high-yield, high-impact

fashion. Second, we wanted to see what the interest in this type

of course was globally and if it would be an effective tool to

help those in developing countries to have a more accessible

training resource.”

To put together the comprehensive course, Dr. Du collabo-

rated with Kellogg ophthalmologists from multiple specialties.

Comprised of weekly lectures by expert cataract surgeons, surgi-

cal video to demonstrate optimal performance of various steps,

weekly quizzes, and a pre-and-post-test, the course teaches the

fundamentals required to perform successful

cataract surgery by phacoemulsification and

extracapsular removal.

“Each step, from preoperative evalu-

ation to postoperative care, is covered to

help prepare residents and trainees for the

operating room, including intraocular lenses,

anesthesia, complications and challenging

cases,” says Dr. Du. “Since most cataract

surgeries are done with the patient awake, it

is imperative that the surgeon gain as much

knowledge as possible prior to entering the

operating room.”

Coursera provides universal access to the world’s best

education, partnering with top universities and organizations

to offer courses online.

“Each step, from preoperative

evaluation to postoperative care,

is covered to help prepare residents

and trainees for the operating

room, including intraocular lenses,

anesthesia, complications and

challenging cases.”

—Elizabeth Du, M.D.

THE EYES HAVE IT: AN APP FOR iOS AND ANDROIDA New Comprehensive Pocket Resource for Ophthalmic Information

Jonathan D. Trobe, M.D., Professor, saw the opportunity to pro-vide greater resources to assist medical and optometric students in learning about ophthalmology. To address this need, Dr. Trobe authored The Eyes Have It, an app for iOS and Android compris-ing 134 eye conditions, 410 images, more than 40 narrated animations and patient videos, six screening examination videos and an eye anatomy review section. “The text contains hyperlinks to supplemental images, nar-rated animations and videos that illustrate the clinical and teach-ing points. A picture-based, multiple-choice quiz allows users to assess their knowledge,” says Dr. Trobe. A well-known educator, Dr. Trobe is the author of The Physician’s Guide to Eye Care, now in its 4th edition.

16

RESIDENT PURSUES INNOVATION IN IMAGING

With a background in physics and bioengineering, it is no

wonder that Tyson N. Kim, M.D., Ph.D., joined Kellogg’s

residency program with a promising project already in hand.

“Kellogg was my top choice for residency because its support

for resident research and innovation is bar none,” says Dr. Kim.

Upon starting his residency, Dr. Kim immediately benefitted

from that support by enrolling in the House Staff Innovation

& Entrepreneurship Program. Designed for residents and

fellows at the University of Michigan and guided by experienced

instructors from across campus and in private industry, the

34-week program provides participants with the tools and

resources needed to creatively address patient needs through

medical innovation.

Dr. Kim plans to continue work on the CellScope Retina

device born of a multi-institutional team including the lab-

oratory of Daniel A. Fletcher, Ph.D., at the University of

California, Berkeley, and Todd P. Margolis, M.D., Ph.D.,

and Jeremy Keenan, M.D., M.P.H., at the University of

California, San Francisco. The device enables a smartphone

to take high-quality, wide-field images of the retina by leverag-

ing the high-resolution imaging, portability, computational

power and wireless data transfer capability of smartphones.

According to Dr. Kim, the implications of this technol-

ogy are far-reaching. For example, he points out that diabetic

retinopathy is one of the leading causes of preventable blindness

in the world, and nearly half of diabetic patients in the United

States fail to receive the recommended annual eye screening.

If more people can be screened by this device, more people can

be treated to prevent or delay vision loss from this disease.

To push the project forward, Dr. Kim came to Kellogg a

month before beginning his residency to screen diabetic patients

with the device. As he continues to gather data, he hopes to

prove that this technology can be used to screen for other blind-

ing eye diseases. Dr. Kim says that the next step is to collaborate

with physicians in the primary care setting to see if medical as-

sistants can acquire images as high quality as those captured by

trained eye care professionals.

“We want to create a powerful, easy-to-use tool that pri-

mary care physicians and other health care providers can use

to easily screen for several eye diseases,” says Dr. Kim. “This

allows ophthalmologists to do fewer screenings while receiving

far more referrals for disease treatment. Our hope is that health

care costs will be lowered, time saved and, most importantly,

that patients receive the vision care they need.”

To learn more about the residency program at Kellogg,

visit: www.kellogg.umich.edu/education/residency.html

First-year resident Tyson Kim, M.D., Ph.D., captures an image of a patient’s retina with his new CellScope Retina device.

2015 SURVEY BY DOXIMITY/U.S. NEWS & WORLD REPORT

IN RESIDENCY PROGRAMS IN THE U.S.#8

RANKED

17

First-year resident Lev Prasov, M.D., Ph.D., chose Kellogg for his residency be-

cause of the broad support for research endeavors. Dr. Prasov, who earned a Ph.D.

from the U-M Department of Human Genetics, will now be able to complete a

research project he started during his fourth year of medical school with the help

of a $100,000 grant from the BrightFocus Foundation. He will study a newly

discovered angle-closure glaucoma gene.

The new gene, called MTRR, is involved in homocysteine metabolism. It was

discovered by studying a large family with iris cysts, which can block the fluid

outflow channels in the eye, leading to an increase in eye pressure and glaucoma.

Collaborating with Ruma Banerjee, Ph.D., Pro-

fessor and Associate Chair in the U-M Depart-

ment of Biological Chemistry, and Rima Rozen,

Ph.D., Professor of Human Genetics and

Pediatrics at McGill University in Montreal,

Dr. Prasov will perform biochemical and

functional studies on the protein that has been

changed by the mutation. The team will also

study the role of the normal protein in the eye

and screen for mutations in the gene in patients

with the forms of glaucoma with which this biochemical pathway has been associ-

ated. Their findings will detail the role of the MTRR gene and its broader meta-

bolic pathway in glaucoma and could lead to the development of future therapies.

“I was drawn to this project because it offered a look into a rare condition

that has not been explored much in ophthalmology literature,” says Dr. Prasov.

“More importantly, though, this project has given me the opportunity to work

with a large family and, based on our research, to possibly give them meaning-

ful information about their condition. It’s very rewarding to be able to connect a

person to a research finding.”

RESIDENT WINS BRIGHTFOCUS GRANT TO CONTINUE MEDICAL SCHOOL RESEARCH

“I was drawn to this project

because it offered a look into a

rare condition that has not been

explored much in ophthalmology

literature.”

—Lev Prasov, M.D., Ph.D.

First-year resident Lev Prasov, M.D., Ph.D., researches a new angle-closure glaucoma gene.

Kellogg Resident Develops Device to Make Eye Drops Easier to Use

Prior to starting his residency, Marius A. Tijunelis, M.D., M.B.A., spent a year at Kellogg as an Innovation Fellow through the U-M Medical Innovation Center. The purpose of this fellowship was to invent, develop and take to market a product that would solve a common problem in the field of ophthalmology. Dr. Tijunelis and his colleague, David Lorch, Ph.D., who was also an Innova-tion Fellow, designed and produced an eye-drop-assist device, the DROPin™. The device fits most types of eye drop bottles and stabilizes the bottle for one-handed use. Once the cap is removed, the bottle is placed through the hole in the device. The triangular end of the DROPin™ rests on the bridge of the nose and the tip of the bottle is centered over the eye. The free hand is then used to hold open the eye while the drop is applied. In July 2013, the DROPin™ became available for purchase on amazon.com, at Kellogg’s Optical Shop and at a hand-ful of pharmacies in the Ann Arbor area. More than 500 DROPin™ devices have been sold to date. Now in his second year of resi-dency, Dr. Tijunelis has noticed that many patients have difficulty properly instilling their medicated eye drops. “I believe that this device helps patients accurately instill their medications resulting in fewer wasted drops and lower medication cost over time,” says Dr. Tijunelis.

18

EYE CARE GOES BACK TO SCHOOLKellogg Partners to Bring Vision Care Services to Underserved Areas

A few years ago, Kellogg optometrist Courtney A. Dewey, O.D.,

spoke to Ypsilanti middle-school students about eye health. That

talk sparked a partnership between Kellogg and the University

of Michigan Health System (UMHS) Regional Alliance for

Healthy Schools (RAHS) to establish an eye clinic at Ypsilanti

Community High School.

RAHS, whose mission is to provide school-based health

programs and clinical services that improve the well-being of

students, their families and communities, was looking for a way

to provide vision services to Ypsilanti’s underserved areas. Dr.

Dewey knew Kellogg could help. In February 2015, the Com-

munity Eye Clinic opened as part of a newly-renovated, school-

based health center featuring a U-M medical team that provides

services such as physical examinations, immunizations, labora-

tory testing and counseling.

Kellogg equipped the eye clinic for Dr. Dewey, who exam-

ines patients two Tuesdays per month, serving approximately

10 students per day. She initially worked through a backlog of

students who needed vision care. When the public schools are

in session, Dr. Dewey has a steady stream of 7th through 12th

graders who come to the clinic if they are having visual symp-

toms or are referred by other members of the medical team.

If students need eyeglasses, Dr. Dewey notifies Kellogg’s

Optical Shop staffers, who obtain the information from

Mi-Chart, UMHS’ electronic medical records system, and ar-

range for the eyeglasses to be manufactured. One of Kellogg’s

opticians then delivers the eyeglasses to the clinic in Ypsilanti.

“RAHS is a great program that has really flown under the

radar,” says Dr. Dewey. “It’s a great example of how UMHS

can help schools serve students and the community. Kellogg

would love to eventually have a presence in all RAHS locations

and to serve as a model for comprehensive school-based health

centers statewide.”

Pediatric optometrist Courtney Dewey, O.D., examines patients at the Ypsilanti Community High School eye clinic.

KELLOGG FACULTY MEMBER RECOGNIZED FOR LEADING OPHTHALMOLOGY AT THE HOPE CLINICProviding Ophthalmic Care for the Uninsured in Our Community

Paula Anne Newman-Casey, M.D., M.S., Assistant Professor, is the recipient of the 2015 University of Michigan Medical School (UMMS) Dean’s Award for Local Community Service for her efforts as the director of the Hope@UMHS-KEC ophthalmology clinic pro-gram to provide ophthalmic care for the uninsured in Ann Arbor and the surrounding areas. "It is quite an honor to receive this award and I feel that it is really a shared accomplishment with all of the faculty and staff from the Kellogg Eye Center who have generously donated their Saturday mornings to provide eye care for those in our community who do not have insurance,” says Dr. Newman-Casey. “Over the last four years, we have provided ophthalmic care to over 850 patients who would have otherwise gone without. I know this program will continue into the future because my colleagues are just that generous." Recognizing UMMS faculty that have made extraordinary contributions to the local, national or global community, this honor carries a $5,000 discretionary academic award.

19

The University of Michigan Medical School and the VA Ann Arbor Healthcare System

(VA) have a decades-long history of collaborating to provide outstanding health care

to military veterans. Kellogg is the main eye care provider at the VA, where more than

90 patients per day are seen. To better handle growing patient volume, the VA eye

clinic recently underwent an expansion.

The renovated clinic increased in size from 10 to 17 exam lanes, all with updated

equipment. To improve patient flow, ophthalmology services have been moved to

one side of the clinic and optometry services are on the other. Kellogg has also gained

access to more operating room space 6-8 times per month.

In addition, Kellogg has added more providers so that there are now 20 physi-

cians providing VA care each week. To supplement comprehensive care, Kellogg offers

a different subspecialty clinic each day. The physicians are supported by a clinic super-

visor, 11 ophthalmic technicians and six residents.

“In recent years, improving patient access while maintaining our high quality has

been our goal,” says Denise A. John, M.D., FRSCS, Assistant Professor and Chief of

Ophthalmology at the VA. “And with more providers, more exam lanes, more techni-

cians and more surgery time, we are better able to meet the demands of our patients.”

Dr. John oversees the day-to-day operations of the eye clinic, including the residents

who complete two, seven-week rotations in each year of their training program. A

new feature is a resident continuity clinic, which allows two third-year residents and

four second-year residents to manage—with the appropriate level of faculty supervi-

sion—their own patients.

“The veterans are extremely appreciative of the care they receive,” says Dr. John.

“And we all work together as a team to put them first.”

EXPANDING AT THE VAMore Space, More Services to Care for Veterans

VA Chief of Ophthalmology Denise John, M.D., oversees the VA eye clinic.

Innovative Safety Check-List Improves Quality of Patient Care

Jennifer S. Weizer, M.D., director of the Kellogg Quality Assurance team, recently led efforts to devise an innovative safety checklist program for ophthalmologists to use in the operating room before, during and after surgery. Once it was put into place, the team monitored surgical adher-ence to the checklist. Results were shared with Kellogg surgeons and staff and then educational interventions were instituted, which led to improved adherence rates. “Collaboration and open communica-tion among our surgical team were the keys to improving adherence rates and making the operating room an even safer place for our patients,” says Dr. Weizer. Upon completion of the checklist project, Dr. Weizer worked with both the University of Michigan Health System and the American Board of Ophthalmology Maintenance of Certification (ABO MOC) programs to obtain approval for Kellogg surgeons to earn ABO MOC credit for their participation. The ABO MOC program is a patient-centered, continuous professional develop-ment tool designed to assess and develop the core competencies essential for provid-ing high-quality patient care. Kellogg’s checklist met the certification requirements of Part 4 of the program—Demonstrating Quality Improvement. “This is the first program of its kind in the country for which the ABO has granted this type of credit,” says Dr. Weizer. “More importantly, it improves patient safety by making it easier for our faculty to achieve the goals of the ABO MOC program.”

20

Jerome Jacobson suffered from glaucoma for most of his life.

Diagnosed as a young adult, Mr. Jacobson’s vision presented

daily concerns and challenges for him. “In all the time I spent

with Jerry, I never knew a day or occasion where, at least in

some way, sight didn’t come up,” says John R. Breen, longtime

friend and co-trustee of the Jerome Jacobson Foundation.

“It was a serious fight he had with the disease.”

In the early 1970s, just after relocating to Michigan,

Mr. Jacobson became a patient of Kellogg glaucoma special-

ist Paul R. Lichter, M.D., M.S., Professor, a relationship that

endured until Mr. Jacobson passed away in 2008.

Mr. Breen describes Mr. Jacobson as a

passionate philanthropist, supporting a long

list of causes with an eye toward fairness and

justice. One of his philanthropic causes was

the Kellogg Eye Center, which became a focus

of the Foundation’s priorities over the past

seven years with major grants awarded for

basic research in glaucoma and international

ophthalmology efforts.

Last year, the Jerome Jacobson Foundation awarded

Kellogg a gift in the amount of $3.5M to support the establish-

ment of the Jerome Jacobson Professorship, a fully endowed

glaucoma professorship ($2.5M), and the endowed Jerome

Jacobson Vision Research Fund ($1M). The gift was announced

by Mr. Breen at Kellogg’s 30th Anniversary celebration held at

the University of Michigan Museum of Art.

“Jerry was a humble man. He was shy about putting his

name to his philanthropy and usually gave gifts anonymously.

This time, we wanted to endow a professorship in Jerome

Jacobson’s name, highlighting his belief in the work that is done

at the Kellogg Eye Center, as he was deeply appreciative of the

treatment he received there,” says Mr. Breen, who directs the

Foundation with co-trustee Louis P. Rubinfield, a relative of Mr.

Jacobson. “It is our hope that these endowments will ensure

that the Eye Center continues to make strides toward eventually

conquering glaucoma.”

Born in New Jersey in 1921, Mr. Jacobson built a distin-

guished career as an economist, holding management posts for

both the Bendix Corporation and Burroughs Corporation in

Michigan, and as president of Robert Nathan Associates, an

economic consulting firm headquartered in

Washington, D.C. He also served as Deputy

Assistant Secretary for Economic Affairs in

the U.S. State Department during the John F.

Kennedy administration.

“As I came to know Mr. Jacobson over

more than 35 years, I began to realize that

he was a particularly careful and thorough

person in everything he did,” says Dr.

Lichter. “The fact that he chose Kellogg as the institution

where he would receive his glaucoma care was an important

vote of confidence, especially after he relocated to Washington,

D.C., yet continued to fly back to Michigan to see me regularly

for his care. We became good friends.”

Dr. Lichter explains that Mr. Jacobson’s approach to

philanthropy was as careful as his selection of medical care.

“Mr. Jacobson evaluated and thought about the causes that

he decided to support. His decision to support Kellogg was an-

other important endorsement,” says Dr. Lichter. “Mr. Jacobson

considered Kellogg to be on the cutting edge of research and

patient care and an organization that has what it takes to find

better treatments, and even a cure, for glaucoma.”

“It is our hope that these endowments

will ensure that the Eye Center contin-

ues to make strides toward eventually

conquering glaucoma.”

—John R. Breen

Paul Lichter, M.D., M.S., Paul Lee, M.D., J.D., and Mr. and Mrs. John Breen.

KELLOGG IS RECIPIENT OF $3.5M GIFT FROM THE JEROME JACOBSON FOUNDATION

Gift Establishes the Jerome Jacobson Professorship and Vision Research Fund

21

Paula Anne Newman-Casey,

M.D., M.S., Assistant Professor, has

created the eyeGuide, a counseling

program supported by a web-based,

tailored educational tool that ad-

dresses adherence rates to glaucoma

medications.

The program helps medical

assistants and technicians provide

high-quality, individualized patient

counseling that might otherwise be

possible only with an ophthalmologist. It begins by showing pa-

tients photographs of a healthy optic nerve, an optic nerve with

glaucoma and their own optic nerve so that they can see the

disease progression. The eyeGuide also features patient stories

to address specific issues such as the expense or side effects of

glaucoma medications. It concludes with the development of an

action plan to help patients integrate taking glaucoma medica-

tions into their daily routine.

“At least one third of glaucoma patients do not take their

medications regularly, creating a significant segment of people

who go on to develop needless vision loss,” says Dr. Newman-

Casey. “We’ve found that this personalized approach really

resonates with our glaucoma patients.”

Brenda L. Bohnsack, M.D., Ph.D.,

Assistant Professor, is studying

the PAX6 gene and its mutations

that are associated with aniridia,

an eye disorder that leads to mal-

formation of almost all structures

of the eye. Approximately 50

percent of individuals with aniridia

have glaucoma and the disorder

can be difficult to treat and can

lead to significant vision loss and blindness.

To learn more about PAX6, Dr. Bohnsack and her team

are collaborating with the U-M Human Embryonic Stem Cell

Center. “We have human embryonic stems cells which were

derived from a family that is affected by aniridia and carries a

mutation in PAX6,” says Dr. Bohnsack. “We are characterizing

these mutant stem cells to better understand the role of this gene

in early human development and as a stepping-off point for

creating potential stem cell treatments for those with aniridia.

With this information, we can try to regenerate or reverse the

dysfunctional tissue we see in this condition.”

Philip J. Gage, Ph.D., Associate

Professor, studies Axenfeld-Rieger

Syndrome (ARS), a congenital

syndrome that is characterized by

abnormalities of the front part

of the eye. Children with ARS

suffer from elevated intraocular

pressure which can lead to early

onset glaucoma in over half of

this young population.

Unlike glaucomas that develop

in adults, ARS is particularly resistant to conventional therapies

and surgical techniques. To address these challenges, Dr. Gage

and his team have generated a designer mouse model to study

what Pitx2, a type of regulatory gene in the cell, does in the

normal course of eye development. “We study the outcomes

when the lab genetically mimics what happens in patients who

suffer from this disease,” says Dr. Gage. “One amazing find-

ing is that this model develops a similar ocular disease to what

humans develop, with alterations in the anterior ocular segment,

elevated intraocular pressure and optic nerve head cupping.”

Julia E. Richards, Ph.D., the

Harold F. Falls Collegiate Professor

of Ophthalmology and Visual

Sciences, and Sayoko E. Moroi,

M.D., Ph.D., Professor, have joined

the International Glaucoma

Genetics Consortium to study

samples from more than 35,000

subjects for genetic risk factors

associated with glaucoma.

“Through the use of genome-

wide technologies, this group identified four new genetic risk

factors for elevated intraocular pressure, the only known

modifiable risk factor for glaucoma,” says Dr. Richards.

“The group also provided data to confirm three other genetic

risk factors for glaucoma that are associated with elevated

intraocular pressure.”

Pooling the resources of many different research groups

was invaluable to the study. “We were able to assemble a large

enough study population to let us detect genetic risk factors that

were not detectable in the smaller study populations assembled

by each of the separate research groups,” says Dr. Richards.

“The samples and data contributed by the group represented

more than 20 years of work by many doctors and researchers.”

UPDATES ON GLAUCOMA RESEARCH AT KELLOGG

22

The Kellogg Eye Center for International Ophthalmology Facilitates International Clinical and Research Activities

The Kellogg Eye Center for International Ophthalmology held

its third annual International Night on October 12, 2015.

The keynote speaker was 2015 Scholar-in-Residence Thomas

Lietman, M.D., the Ruth Lee and Phillips Thygeson Distin-

guished Professor and Director of the F. I. Proctor Foundation

for Research in Ophthalmology at the University of California,

San Francisco. The Foundation was established in 1947 with

the purpose of eradicating trachoma worldwide. Dr. Lietman

delivered a presentation Will the Last Case of Trachoma

Please Stand Up?

Dr. Lietman’s work centers around mass antibiotic distribu-

tions for eliminating trachoma and the possible collateral effects

of these distributions, including selecting for resistant organisms

and impact on childhood mortality. “At the Proctor Founda-

tion, we’re looking for research questions where, if we are lucky

enough, an answer could have leverage and impact on a far

larger population,” says Dr. Lietman. “Whether that research

is done in San Francisco—or Nepal, Ethiopia or South India—

that’s what we’re looking for.”

For the past 20 years, Dr. Lietman has studied trachoma

and infectious corneal ulcers, working in Egypt, Nepal,

Ethiopia, India and Niger. Dr. Lietman has been the principal

investigator on several NIH-NEI and Gates Foundation random-

ized trials. He is also part of the infectious disease modeling

group at Proctor.

Dr. Lietman explained that, at the present time, there is a

reasonable solution for controlling trachoma with mass anti-

biotic treatments and other measures. “I think we’re going to

be able to control the disease to a level that the World Health

Organization currently sees as satisfactory,” says Dr. Lietman.

H. Kaz Soong, M.D., Jonathan Trobe, M.D., Monte Del Monte, M.D., Thomas Lietman, M.D., Paul Lee, M.D., J.D., Christine Nelson, M.D., Timothy Johnson, M.D., and Joseph Kolars, M.D., at Kellogg's third International Night.

FORGING NEW RELATIONSHIPS IN GLOBAL OPHTHALMOLOGY

Thomas Lietman, M.D., and Zvi Kresch, M.D.

23

“I’m a little worried about what is going to happen after that.

I don’t think trachoma is going to rebound and come back with

a vengeance if we stop control programs, but I do think we have

an opportunity to completely eradicate trachoma. And if we

don’t jump on that opportunity now, I don’t think the resources

are going to be available in the future.

Trachoma could become a forgotten dis-

ease and linger on for a few decades if we

don’t stamp it out right now. On the other

hand, trachoma could be the first bacterial

disease that we eradicate.”

Dr. Lietman expressed great admira-

tion for the scope of Kellogg’s international

program. “The Kellogg Eye Center for

International Ophthalmology has quickly become one of the

leading programs in the country. It’s difficult to believe that it

has only been in existence for three years,” says Dr. Lietman.

“The Center has forged strong international collaborations with

top institutions on different continents. While I knew that the

U-M Department of Ophthalmology was one of the preeminent

departments in the world, this visit let me see how wonderful

the people are at this institution.”

Dr. Lietman commented on the components of global

outreach in academic health centers, including patient care, edu-

cation and research. “I think the Kellogg Eye Center is perhaps

the leader in the educational aspect of global health,” he says.

“Kellogg is really living the idea that teaching goes both ways.

Residents at Kellogg, along with fellows and medical students

at the University of Michigan Health System, have the oppor-

tunity to travel to incredible locations and hospitals around the

globe to meet amazing physicians and surgeons who can teach

them about complex eye diseases. In turn, those physicians and

surgeons can come to to Kellogg to participate. Kellogg faculty

members also teach abroad, so it’s really a very reciprocal

relationship.”

Ariane D. Kaplan, M.D., Instructor and ophthalmology

medical student clerkship director, served as moderator for this

event. Presentations included: 1) An Academic Approach to

Global Health Engagement by Timothy

R.B. Johnson, M.D., Professor and Chair

of the U-M Department of Obstetrics and

Gynecology; 2) Planting Rice in Haiti:

Starting out in Global Health by Vicky

Koski-Karell, M2; 3) Engineering Inno-

vations for Patient Care, Teaching, and

Research in Ophthalmology by Roland

Chen, Ph.D., Research Investigator at the

U-M College of Engineering; and 4) Kellogg in Ethiopia by

Zvi A. Kresch, M.D., Instructor.

Roland Chen, Ph.D., Research Investigator at the U-M College of Engineering.Gurpreet Rana, MLIS, media specialist at the Taubman Health Sciences Library, speaks to Tania Piotrowski, administrative director of U-M Global Reach, during International Night.

Donna Donato, administrative director of the Center for International Ophthal-mology, Kellogg faculty member Christine Nelson, M.D., Dayakar Yadalla, M.D.,

oculoplastic surgeon and residency program director at the Aravind Eye Care System (Pondicherry), and Kellogg faculty member César Briceño, M.D.

“I think the Kellogg Eye Center is perhaps

the leader in the educational aspect of

global health. Kellogg is really living the

idea that teaching goes both ways.”

—Thomas Lietman, M.D.

24

Jonathan B. Greene, M.D., Assistant Professor, and Monte A.

Del Monte, M.D., the Skillman Professor of Pediatric Ophthal-

mology, led the Kellogg team that has served as advisors to

St. Paul Hospital Millennium Medical College in Addis Ababa,

Ethiopia, in establishing a four-year residency

training program for ophthalmologists.

Drs. Greene and Del Monte collaborated

with St. Paul’s Ophthalmology Chair Bezawit

Tadegegne, M.D., and Ophthalmology

Program Director Lemlem Tamrat, M.D.,

in developing the new program, one of only

four such programs in Ethiopia.

“The first six residents began their train-

ing last September and we are excited to see

how our faculty and experience with medical

education can be used to enable the growth of their program,”

says Dr. Greene. “We hope to assist our Ethiopian colleagues

in building a training program and eye care center that will

become a regional center of excellence. Graduates will be

instrumental in elevating the quality of eye care not only in

Ethiopia but in the entire East Africa region.”

During the preliminary stages of development, Drs. Tadegegne

and Tamrat spent an intensive week at Kellogg visiting the

clinics and operating rooms, attending confer-

ences and interviewing residents and faculty

to find out how our program works. “We are

impressed with the Hospital’s knowledge,

energy and determination to succeed in this

critical enterprise in ophthalmic education,”

says Jonathan D. Trobe, M.D., Professor and

co-director of the Kellogg Eye Center for Inter-

national Ophthalmology.

The initiative was spearheaded by Senait

Fisseha, M.D., Professor of Obstetrics and

Gynecology at the University of Michigan, who has had a major

role in developing training programs in obstetrics and gynecol-

ogy, internal medicine, radiology and general surgery at St. Paul

Hospital Millennium Medical College.

"We hope to assist our Ethiopian

colleagues in building a training

program and eye care center that

will become a regional center of

excellence.”

—Jonathan B. Greene, M.D.

KELLOGG TEAM HELPS ETHIOPIAN HOSPITAL ESTABLISH A WORLD-CLASS RESIDENCY TRAINING PROGRAM

Jonathan Greene, M.D., (left), and Monte Del Monte, M.D., (right), with Elias Hailu Gebreab, M.D., President of the Ophthalmological Society of Ethiopia.

Michael Smith-Wheelock, M.D., with Bezawit Tadegegne, M.D., Chair of Ophthalmology, and Lemlem Tamrat, M.D., Director of the Ophthalmology Residency Program,

at St. Paul’s Hospital in Addis Ababa, Ethiopia.

Since July 2014

43 INTERNATIONAL VISITORS TRAVELED FROM 16 DIFFERENT COUNTRIES

18 FACULTY MEMBERS TRAVELED TO 20 COUNTRIES WORLDWIDE

25

TWO KELLOGG FACULTY ARE AWARDED TAUBMAN MEDICAL RESEARCH INSTITUTE HONORS

Kellogg scientists and their laboratory groups work

steadily to find new treatments and cures for blinding

eye diseases, such as diabetic retinopathy, age-

related macular degeneration and retinitis pigmen-

tosa. The University of Michigan A. Alfred Taubman

Medical Research Institute plays a key role in funding

our research initiatives.

Thomas W. Gardner, M.D., M.S., Profes-

sor, was named a Taubman Institute Scholar

by the University of Michigan A. Alfred

Taubman Medical Research Institute. Dr.

Gardner’s research focuses on understand-

ing why diabetes damages the retina, with

the goal of helping people with the disease

maintain their vision.

With this honor, he will receive a three-

year renewable research grant of $50,000

annually, followed by $5,000 per year

indefinitely.

“The Taubman Institute fosters high-

risk new ideas and this funding provides

the opportunity to determine if retinal func-

tion can be restored in people who have

diabetic retinopathy,” says Dr. Gardner.

“It would be very difficult to conduct this early-stage work

without the support of the Taubman Institute. Mr. Taubman

has left an enduring legacy for which we are most grateful.”

Rajesh C. Rao, M.D., Assistant Professor,

was appointed the Leslie H. and Abigail S.

Wexner Emerging Scholar by the University

of Michigan A. Alfred Taubman Medical

Research Institute. Dr. Rao’s research focuses

on using stem cell biology and epigenetics

as languages to decipher the pathogenesis of

retinal disease and future treatments. With

this award, he will receive support for his research for a period

of five years at $50,000 per year for the first three years and

$25,000 per year for the last two years.

“I am grateful for the transformative gift that Mr. and

Mrs. Wexner and the A. Alfred Taubman Medical Research

Institute have provided to further our work in finding new

ways to diagnose and treat blinding eye diseases,” says Dr. Rao.

“Their support will enable us to use epigenetics and stem cell

biology to better understand the basic biological mechanisms

that control stem cell behavior so that cells

that are lost in blinding eye diseases can be

regenerated. Their gift will accelerate our

collaborative, precision medicine efforts with

fellow Taubman Scholars to link patients

with lethal diseases like eye cancer to targeted

treatments based on a tumor's unique genetic

and epigenetic profile.”

The Institute’s Emerging Scholars Pro-

gram was created to support and encourage

early-career physician-scientists whose labo-

ratory work aims to translate basic research into new treatments

for disease. The program connects U-M Medical School faculty

members at the assistant professor level with philanthropists

who pledge to support the physicians’ research.

“It would be very difficult to conduct this

early-stage work without the support of

the Taubman Institute. Mr. Taubman has

left an enduring legacy for which we are

most grateful.”

—Thomas W. Gardner, M.D., M.S.

The University of Michigan A. Alfred Taubman Medical Research Institute is housed in the Biomedical Science Research Building.

26

For the first time in its history, the

Retina Society and its 650 distin-

guished members are being led by

a Kellogg physician. At the 48th

annual meeting of the Society in

Paris last year, Mark W. Johnson,

M.D., Professor, began his two-

year term as president.

“It is a tremendous privilege

for me to have this opportunity

to serve my wonderful colleagues

in the Retina Society who have

been huge sources of inspira-

tion throughout my career,” says Dr. Johnson. “I believe this

appointment is, in part, an indication of the esteem with which

ophthalmologists around the country regard the programs

and faculty of the Kellogg Eye Center and the University of

Michigan.”

Prior to taking over as president, Dr. Johnson served on the

Society’s executive committee for six years. He was elected sec-

retary in 2009 and then served as treasurer and vice president.

Throughout his 25-year career, Dr. Johnson, who is a fellow of

the American Academy of Ophthalmology (AAO), has amassed

many accolades, including the AAO Honor Award (1995) and

the AAO Senior Achievement Award (2005). He was elected to

active membership in the American Ophthalmological Society in

2005 and is recognized in Best Doctors in America and Guide to

America’s Top Physicians. Dr. Johnson has served as the Associ-

ate Examiner for the American Board of Ophthalmology since

1995 and serves on the editorial boards of the American Journal

of Ophthalmology, Retina and Retinal Physician.

Dr. Johnson heads Kellogg’s Retina and Uveitis Service. His

clinical research interests include pharmacotherapies for macular

diseases and pathogenesis and treatment of vitreomacular

interface disorders. Dr. Johnson served as principal investigator

and Data and Safety Monitoring Committee member for numer-

ous national multicenter clinical trials in age-related macular

degeneration, retinal vascular disease and vitreoretinal disorders.

He lectures widely on topics in macular and vitreoretinal disease

and has published over 175 articles and book chapters. Dr.

Johnson completed medical school at the University of Utah in

1984 and residency at Kellogg in 1988, serving as chief resident

in his final year. He completed medical retina and vitreoretinal

surgery fellowships at the Bascom Palmer Eye Institute in 1990

and then joined the Kellogg faculty as an assistant professor.

KELLOGG FACULTY MEMBER LEADS SOCIETY OF RETINAL SPECIALISTS IN THE U.S.

KELLOGG RETINAL SPECIALIST AWARDED THE RETINA SOCIETY AWARD OF MERIT IN RETINA RESEARCH

Thomas W. Gardner, M.D., M.S., Profes-sor, is the recipient of the Retina Society Award of Merit in Retina Research honor-ing Charles L. Schepens. This honor recog-nizes outstanding national achievement in retina research and provides a $50,000 cash prize that includes $45,000 for the recipient’s research and a $5,000 honorarium. The award was presented at the annual meeting of the Retina Society in Paris. “The Award of Merit in Retina Re-search is greatly appreciated because it is given by the Retina Society, a lead-ing international organization of retinal

specialists,” says Dr. Gardner. “This award recognizes the contributions of many faculty members at the Kellogg Eye Center. The funds from the prize will support ad-ditional research.” The mission of the Retina Society is to reduce worldwide visual disability and blindness by promoting the education and professional interaction of vitreoretinal spe-cialists, providing optimal care for patients with vitreoretinal diseases, and encourag-ing, through clinical and basic research, the discovery and development of new means to further patient care.

27

Kellogg Fellow Awarded the Retina Society’s Margherio Award

Devon Ghodasra, M.D., Kellogg vitreo-retinal surgical fellow, won the presti-gious Raymond R. Margherio Award at the 48th Annual Retina Society Meeting in Paris last year for his research on vitreous cytokines. Established to support research into macular disease and the development of new technologies for macular surgery, the fund supports an award to a vitreo-retinal fellow of an active member of the Society. Dr. Ghodasra was spon-sored by Professor Thomas W. Gardner, M.D., M.S. The award covered the travel and lodging costs of attending the annual meeting, where Dr. Ghodasra presented his research findings. Dr. Ghodasra is Kellogg’s second recipient of the Margherio Award, join-ing former fellow Edward F. Hall, M.D., who won the award in 2008 with the support of Professor David N. Zacks, M.D., Ph.D.

2015 GRADUATING RESIDENTS

Courtney Y. Kauh, M.D., M.S., fellow in oculoplastics, University of Wisconsin, Madison, Wisconsin

Mehnaz Khan, M.D., M.S., fellow in vitreo-retinal surgery, Cleveland Clinic, Cleveland, Ohio

Lee M. Kiang, M.D., Ph.D., Graduate Chief Resident, Kellogg Eye Center, Ann Arbor, Michigan

Matthew W. Manry, M.D., compre-hensive ophthalmologist, Kellogg Eye Center, Ann Arbor, Michigan. He will enter a vitreo-retinal fellowship.

Monica A. Michelotti, M.D., fellow in vitreo-retinal surgery, Oregon Health & Science University, Portland, Oregon

Melisa Nika, M.D., fellow in glaucoma, Kellogg Eye Center, Ann Arbor, Michigan

Andrew W. Stacey, M.D., M.S., fellow in ocular oncology, Moorfields Eye Hospital, NHS Foundation Trust, London, England

2015 GRADUATING CLINICAL FELLOWS

Victoria M. Addis, M.D., assistant professor and glaucoma specialist, University of Pennsylvania, Philadelphia, Pennsylvania

Sejal Rajendra Amin, M.D., cornea specialist, Henry Ford Hospital, Detroit, Michigan

Lulu Bursztyn, M.D., FRCSC, assistant professor and neuro-ophthal-mology specialist, Western University, London, Ontario

Catherine S. Choi, M.D., assistant professor and pediatric ophthalmology and strabismus specialist, Tufts University, Boston, Massachusetts

Steven R. Cohen, M.D., retina specialist, Retina Associates, PA, Kansas City, Missouri

Marina A. Eisenberg, M.D., pediatric ophthalmology and strabismus special-ist, Cleveland Clinic, Cleveland, Ohio

Kristopher M. Kowal, M.D., neuro-ophthalmology specialist, Surrey Memorial Hospital, Surrey, British Columbia

Andrew W. Lewis, M.D., glaucoma specialist, U.S. Army, Wilford Hall Ambulatory Surgical Center, San Antonio, Texas

Steven G. Odaibo, M.S., M.D., retina specialist, Medical Associates, Dubuque, Iowa

Dolly A. Padovani-Claudio, M.D., Ph.D., assistant professor and pediatric ophthalmology and strabismus special-ist, Vanderbilt University, Nashville, Tennessee

Fatemeh Rajaii, M.D., Ph.D., assistant professor and oculoplastics specialist, Johns Hopkins University, Baltimore, Maryland

Daniel Sand, M.D., cornea specialist, Kaiser Permanente Medical Group, Los Angeles, California

2015 GRADUATING RESEARCH FELLOWS

Mark T. Bolinger, Ph.D., Molecular and Integrative Physiology, University of Michigan, Ann Arbor

Our residents and fellows are the future leaders in ophthalmology and visual sciences. After training, most residents go on to fellowships at other major institutions and our fellows pursue their subspecialties in private practice or at academic medical centers. See where our 2015 graduating residents and fellows are now:

RESIDENTS AND FELLOWS Department of Ophthalmology and Visual Sciences

FELLOWSHIPS AT KELLOGGTo learn more about the fellowship opportunities at Kellogg, visit: www.kellogg.umich.edu/education/fellow.html

28

Two of Kellogg’s most capable young faculty members earned

career development professorships to advance their research.

Brenda L. Bohnsack, M.D., Ph.D., Assistant Professor, was in-

stalled as the Helmut F. Stern Career Development Professor of

Ophthalmology and Visual Sciences, and Joshua D. Stein, M.D.,

M.S., Associate Professor, was installed as the Edward T. and

Ellen K. Dryer Career Development Professor in Ophthalmol-

ogy and Visual Sciences. Both professorships were established to

provide junior faculty with important research support and are

held for five years.

Dr. Bohnsack, a member of the Pediatric Ophthalmology

and Adult Strabismus Service, as well as the Glaucoma, Cata-

ract, and Anterior Segment Disease Service at Kellogg, special-

izes in the medical and surgical management of congenital

eye diseases. The goal of her research is to create molecularly

targeted therapies to cure these diseases.

“This professorship will allow me to continue my work in

understanding the basis of congenital eye diseases in the hopes

of applying this knowledge to prevent childhood blindness,”

says Dr. Bohnsack.

Dr. Bohnsack earned her Ph.D. in molecular and cellular

biology in 2004 and her M.D. in 2006 from the Baylor Col-

lege of Medicine. She went on to complete her residency (2010)

and a postdoctoral fellowship (2011) at Kellogg and a Pediatric

Ophthalmology and Adult Strabismus fellowship at Duke

University (2012). Dr. Bohnsack then returned to Kellogg to

join the faculty.

The Stern Professorship, previously held by Alon Kahana,

M.D., Ph.D., Associate Professor, was established by Mr. Stern,

an Ann Arbor businessman and philanthropist. Mr. Stern grew

up in Germany and settled in Ann Arbor in 1942, where he

served as president of Industrial Tectonics and later as president

of Arcanum Corporation. Mr. Stern generously supports numer-

ous schools and projects at the University of Michigan and

believes in bolstering the University's excellence as a whole.

He is a longtime supporter of the mission of the Kellogg Eye

Center and served as chairman of the Community Advisory

Board for Kellogg’s expansion campaign.

Joshua D. Stein, M.D., M.S., a member of the Glaucoma,

Cataract, and Anterior Segment Disease Service, heads Kellogg’s

Center for Eye Policy and Innovation, which performs cutting-

edge research that translates billions of individual data points

into results that can ultimately save patients’ vision and improve

their lives.

“I am enormously grateful to the Dryer Charitable Foun-

dation for supporting our ongoing efforts to push technologi-

cal boundaries with the ultimate aim of improving the quality

and affordability of eye care and patients’ access to it,” says

Dr. Stein. “Edward and Ellen Dryer’s beautiful decades-long

partnership and their respective pioneering careers will provide

meaningful inspiration as my colleagues and I forge ahead

with exciting collaborative research projects.”

Dr. Stein earned his M.S. in Evaluative Clinical Sciences

from Dartmouth Medical School in 1997 and his M.D. from

Thomas Jefferson University in 2001. He completed his residen-

cy at New York University (2005) and a Glaucoma fellowship

at Duke University (2007). Dr. Stein joined the faculty at Kellogg

in 2007 and then earned a second M.S. in Health and Health

Care Research at U-M in 2010.

The Dryer Professorship was established by the Dryer

Foundation, which was formed through the estate of the Dryers,

who lived in Detroit and passed away within months of each

other in 2010. Mr. Dryer, an international banking executive,

was struck with blindness in the middle of his career. Mrs. Dryer

was an advertising pioneer who served as the first woman media

director at W.B. Doner & Company. The Dryer Professorship

was previously held by Grant M. Comer, M.D., M.S., Assistant

Professor.

Brenda Bohnsack, M.D., Ph.D., and Joshua Stein, M.D., M.S., earn career development professorships to further their research.

KELLOGG FACULTY MEMBERS EARN PROFESSORSHIPS TO ADVANCE THEIR PROMISING RESEARCH

29

Meet Kellogg’s New Faculty

Angela R. Elam, M.D., clinical lecturer, has joined the faculty of the Glaucoma, Cataract, and Anterior Segment Disease Service and sees patients in Kellogg’s Northville and Ypsilanti offices. Dr. Elam earned her medical degree from Duke University and completed her residency at the University of Pittsburgh. She then completed her fellowship in glau-coma at Kellogg. Dr. Elam’s research focuses

on disparities in eye care, eye care utilization and health services.

Yannis M. Paulus, M.D., assistant profes-sor, has joined the faculty of the Retina and Uveitis Service and sees patients in Kellogg’s Grand Blanc office. Dr. Paulus earned his medical degree and completed his residency at Stanford University. He then completed a medical and surgical vitreoretinal fellowship at the Wilmer Eye Institute of Johns Hopkins University. Dr. Paulus holds a joint appoint-

ment in the U-M Department of Biomedical Engineering and his research focuses on the development of novel retinal imaging systems and therapeutic techniques and technologies, including photoacoustic imaging, molecular imaging, restorative retinal laser therapy and surgical techniques.

Julie M. Rosenthal, M.D., clinical instruc-tor, has joined the faculty of the Retina and Uveitis Service and sees patients in Kellogg’s Grand Blanc office as well as at the VA Ann Arbor Healthcare System. Dr. Rosenthal earned her medical degree from the University of Pennsylvania and completed her residency at the Wills Eye Institute of Thomas Jefferson University. She completed her fellowship in vit-

reoretinal surgery at the Casey Eye Institute at the Oregon Health & Science University and, before joining Kellogg, Dr. Rosenthal served as a retinal specialist at Retinal and Ophthalmic Consultants, P.C., in Northfield, New Jersey.

Manjool Shah, M.D., clinical instructor, has joined the faculty of the Glaucoma, Cataract, and Anterior Segment Disease Ser-vice and sees patients in Kellogg’s Ann Arbor and Grand Blanc offices. Dr. Shah earned his medical degree from Washington University in St. Louis and completed his residency at the Casey Eye Institute at the Oregon Health & Science University. He then completed

a fellowship in glaucoma and advanced anterior segment surgery at the University of Toronto.

Upcoming CME Programs

For more information or to register for these programs, visit: www.kellogg.umich.edu/education/cmeoverview.html

For questions, contact Jennifer Burkheiser, CME Coordinator, at 734.763.2357 or kelloggCME@umich.edu.

Each year, Kellogg offers an informative series of continuing medical education programs designed to share new approach-es to the diagnosis and management of eye disease across subspecialties. Below are our upcoming programs:

Saturday, March 12, 2016Tri-City Regional Update Conference9 a.m. – noonThe Conference Center at Apple MountainFreeland, Michigan

Application will be submitted for 3.0 AMA PRA Category 1 continuing medical education credits

Friday, June 10–Saturday, June 11, 201688th Annual Spring Postgraduate Conference and 32nd Annual Research Day8 a.m.–5 p.m.Kellogg Eye CenterAnn Arbor, Michigan

Application will be submitted for 15.0 AMA PRA Category 1 continuing medical education credits.

Friday, September 30, 201622nd Annual Fall Reunion Day8 a.m.–4:15 p.m.Kellogg Eye CenterAnn Arbor, Michigan

Application will be submitted for 5.5 AMA PRA Category 1 continuing medical education credits.

30

David A. Antonetti, Ph.D.Editor, Tissue BarriersStudy Section, Diseases and Pathophysiology of the Visual System, National Institutes of Health

Steven M. Archer, M.D.Best Doctors in AmericaCastle Connolly Top DoctorsSenior Achievement Award, American Academy of Ophthalmology

Cagri G. Besirli, M.D., Ph.D.Best Doctors in AmericaTop 40 under 40 Power List, The OphthalmologistCommercial Relationships Committee, Association for Research in Vision and Ophthalmology

Jill E. Bixler, M.D.Best Doctors in America

Brenda L. Bohnsack, M.D., Ph.D.Best Doctors in America

César A. Briceño, M.D.Best Doctors in America

Grant M. Comer, M.D., M.S.Best Doctors in America

Theresa M. Cooney, M.D.Best Doctors in AmericaRegional Director, Michigan Society of Eye Physicians and Surgeons

Wayne T. Cornblath, M.D.Best Doctors in America

Lindsey B. De Lott, M.D.Best Doctors in America

Monte A. Del Monte, M.D.America’s Top DoctorsCastle Connolly Top DoctorsLife Fellow, American Academy of Ophthalmology Lifetime Achievement Award, American Association for Pediatric Ophthalmology and Strabismus Chairman and Annual Meeting Organizer, American Association for Research in Strabismus Fellowship Directors' Committee, American Association for Pediatric Ophthalmology and StrabismusGrant Reviewer, Scientific Review Committee, Medical Advisory Board, Knights Templar Eye Research Foundation

Monte A. Del Monte, M.D. (cont.)Grant Reviewer, Scientific Advisory Committee, National Priorities Research Program, Qatar National Research FundSection Chair, Editorial Committee for Eye Wiki Online Encyclopedia, American Academy of OphthalmologySection Chair, Pediatric Ophthalmology and Strabismus, American Academy of OphthalmologySenior Consultant, International Affairs Committee, American Association for Pediatric Ophthalmology and StrabismusVice President and President-Elect, The Costenbader Pediatric Ophthalmology Society

Hakan Demirci, M.D.Best Doctors in AmericaSenior Achievement Award, American Academy of Ophthalmology Anwar Shah Retina Lecture, Alumni & Residents Day 2015, Department of Ophthalmology, St. Louis University

Raymond S. Douglas, M.D., Ph.D.Best Doctors in America

Susan G. Elner, M.D.Best Doctors in America

Victor M. Elner, M.D., Ph.D.Best Doctors in AmericaCastle Connolly Top Doctors

Jerome I. Finkelstein, M.D.Best Doctors in America

Patrice E. Fort, Ph.D., M.S.Academic Editor, Ophthalmology Research: An International JournalEditorial Board, Journal of Clinical and Experimental OphthalmologyGrant Reviewer, Research Grant Review Committee, American Diabetes AssociationGrant Reviewer, "Societal challenges” Grant Applications, French National Research AgencyGrant Reviewer, “Tender offers” Grant Applications, Institut Carnot Voir et Entendre, Paris, France

Bruce A. Furr, C.O., Ph.D.Lancaster Medal, American Association of Certified Orthoptists Board of Directors, Foundation for Orthoptic Research in America

Christopher Gappy, M.D.Best Doctors in AmericaRules and Bylaws Committee, American Association for Pediatric Ophthalmology and Strabismus

FACULTY HONORS AND RECOGNITION JULY 1, 2014 — SEPTEMBER 30, 2015

31

Thomas W. Gardner, M.D., M.S.Best Doctors in AmericaGold Fellow, Association for Research in Vision and OphthalmologyAssociate Editor, DiabetesGrant Review Panel, American Diabetes AssociationThe Retina Society Award of Merit in Retina ResearchCharles L. Schepens Lecture, The Retina Society Annual Meeting3rd Joseph Sassani Alumni Lecture, Department of Ophthalmology, Penn State College of Medicine

Hilary M. Grabe, M.D.Best Doctors in America

John R. Heckenlively, M.D.Best Doctors in AmericaCastle Connolly Top DoctorsAssociate Editor, EyeEditorial Board and Founding Editor, Documenta OphthalmologicaGrant Reviewer, National Institutes of HealthGrant Reviewer, Foundation Fighting BlindnessGrant Reviewer, Fight for Sight

K. Thiran Jayasundera, M.D.Top 40 under 40 Power List, The Ophthalmologist

Denise A. John, M.D.Best Doctors in America

Mark W. Johnson, M.D.Best Doctors in AmericaCastle Connolly Top DoctorsPresident-Elect and Vice President, The Retina SocietyEditorial Board, American Journal of Ophthalmology, Retina, and Retinal PhysiciansScientific Program Chair, The Retina Society Annual Meeting 2015Mark J. Daily Retina Lecture, Department of Ophthalmology, Loyola University

Alon Kahana, M.D., Ph.D.Best Doctors in AmericaEditorial Board, Oculoplastic Surgery Section, Ocular Surgery NewsEditorial Group, Basic and Clinical Science Course, Section 2: Fundamentals, AAO PublicationsPhysician-Scientist Award, Research to Prevent Blindness Joan & Gordon Bergy, M.D. Lecture in Vision Science, “Gained in Translation” Vision Conference, University of Washington

Paul P. Lee, M.D., J.D.Best Doctors in AmericaCastle Connolly Top DoctorsEditorial Board, JAMA-OphthalmologyAdvisory Board, Hoskins Center for Patient Safety and Quality, Foundation of the American Academy of OphthalmologyBoard of Directors, American Board of OphthalmologyBoard of Governors/Immediate Past Chair, Association for Research in Vision and Ophthalmology Foundation8th Annual M. Bruce Shields Lectureship, Yale UniversityAmerican Glaucoma Society Lecture, American Glaucoma Society Annual MeetingRobertson Lecture, University of Texas Medical BranchShaffer-Hetherington-Hoskins Lecture, 19th Annual Glaucoma Symposium, Glaucoma Research FoundationJ. Britto Distinguished Lecture, University of Sao Paulo, Sao Paulo, Brazil

Paul R. Lichter, M.D., M.S.Best Doctors in AmericaCastle Connolly Top DoctorsAssociate Editor, American Journal of OphthalmologyFoundation Board of Directors, International Council of OphthalmologyKnauer Lecture, American Eye Study ClubFralick Lecture, Department of Ophthalmology, University of Michigan

Michael J. Lipson, O.D.Secretary, Scleral Lens Education Society

Shahzad I. Mian, M.D.Best Doctors in AmericaCastle Connolly Top DoctorsEditorial Board, CorneaGuest Editor, Current Opinion in OphthalmologyBoard of Directors, Cornea SocietyBoard of Directors, Eye Bank Association of AmericaCo-Chair, Cornea Sub-specialty Day, American Academy of OphthalmologyCouncil Credentials Committee, American Academy of OphthalmologyMedical Director, Eversight MichiganProgram Directors Council, Association for University Professors in OphthalmologyVice Chair, Accreditation Board, Eye Bank Association of AmericaVice Chair, Residency Review Committee, Accreditation Council for Graduate Medical EducationSenior Achievement Award, American Academy of Ophthalmology

FACULTY HONORS AND RECOGNITION JULY 1, 2014 — SEPTEMBER 30, 2015

32

Sayoko E. Moroi, M.D., Ph.D.Best Doctors in AmericaCohen-Merck Lecture, 37th Midwest Glaucoma Symposium, Indiana University School of Medicine

David C. Musch, Ph.D., M.P.H.Editorial Board, Eye and VisionEditorial Board, JAMA OphthalmologyEditorial Board, RetinaAdvisory Group, Cochrane Collaboration Eyes and Vision Group US Project Ophthalmic Technology Assessment Committee, American Academy of Ophthalmology Preferred Practice Patterns Committee, American Academy of OphthalmologyReview Committee, Prevent Blindness Joanne Angle Investigator Award Grant Application Reviewer, Special Emphasis Panels, National Institutes of Health Scientific Reviewer, Health and Medical Research Fund and Innovation and Technology Support Programme, Government of the Hong Kong SAR, People’s Republic of China Scientific Reviewer, National Medical Research Council, Government of SingaporeChair, Data and Safety Monitoring Committee, Corneal Preservation Time Study, National Institutes of Health Chair, Data and Safety Monitoring Committee, Sirolimus Treatment of Geographic AMD, National Institutes of Health and Santen, Inc. Chair, Data and Safety Monitoring Committee, Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2), National Institutes of Health Data & Safety Monitoring Committee, META-MUST trials, National Institutes of Health Data & Safety Monitoring Board, Stopping Anti-TNF Agents in Rheumatoid Arthritis (STARA), National Institutes of Health and MedStar Health Research Institute

Christine C. Nelson, M.D.Best Doctors in AmericaCo-Chair, Oculoplastics Curriculum Development Committee, International Council of Ophthalmology

Howard R. Petty, Ph.D.Special Emphasis Panel, Member Conflict: Biology, Pathophysiology and Diseases of the Visual System (ZRG1BDCN-L 02M), National Institutes of HealthSpecial Emphasis Panel, Ocular Diseases Pathophysiology and Therapeutic Approaches (ZRG1BDCN-R 5M ), National Institutes of Health

Donald G. Puro, M.D., Ph.D.Best Doctors in America

Rajesh C. Rao, M.D.Grant Review Panel, France Ministry of Health Delegate, Congressional Briefing and Emerging Vision Scientists Reception, National Alliance for Eye and Vision Research Emerging Vision Scientists Program Editorial Panel, Innovative Retina Surgical Video Series, American Society of Retina Specialists

Julia E. Richards, Ph.D.Editorial Board, G3: Genes, Genomes, GeneticsScientific Advisory Board, The Glaucoma FoundationScientific Reviewer, International Retina Research FoundationDr. Douglas H. Johnson Award in National Glaucoma Research, Bright Focus Foundation

Frank W. Rozsa, Ph.D. Communicators Award, Association for Research in Vision and Ophthalmology

Roni M. Shtein, M.D., M.S.Best Doctors in AmericaMedical Advisory Board, Eye Bank Association of AmericaMedical Director, Eversight MichiganMethodologist, Cornea & Anterior Segment Disorders Panel, Ophthalmic Technology Assessment Committees, American Academy of OphthalmologyMethodologist, Refractive Management/Intervention Panel,

Terry J. Smith, M.D.Best Doctors in America

Michael W. Smith-Wheelock, M.D.Best Doctors in America

H. Kaz Soong, M.D.Best Doctors in AmericaMedical Director, Eversight Michigan

Joshua D. Stein, M.D., M.S.Best Doctors in AmericaLeadership Development Program XVIII, class of 2016, American Academy of Ophthalmology AcademyStanding Committee on Eye Care and Ear, Nose, and Throat Conditions, National Quality ForumShaffer Grants for Innovative Research, Glaucoma Research Foundation22nd Annual Roger P. Mason, Sr., M.D. Lecture, Howard University, Washington D.C.

FACULTY HONORS AND RECOGNITION JULY 1, 2014 — SEPTEMBER 30, 2015

33

Alan Sugar, M.D.Best Doctors in AmericaEditor-in-Chief, Cornea, Journal of the Cornea SocietyMedical Director, Eversight MichiganMedical Advisory Board, Eye Bank Association of AmericaResearch Committee, Eye Bank Association of AmericaFrank Polack, M.D., Memorial Lecture in Cornea, University of Florida

Debra A. Thompson, Ph.D.Editorial Board, Experimental Eye Research

Susan S. Thoms, M.D.Best Doctors in America

Jonathan D. Trobe, M.D.Best Doctors in AmericaCastle Connolly Top DoctorsArthur Wolintz Memorial Lecture, Department of Ophthalmology, State University of New York (SUNY) Downstate Medical CenterPhilip C. Hessburg Lecture, 2015 Annual Alumni Meeting, Department of Ophthalmology, Henry Ford HospitalA.E. Finley Distinguished Visiting Professor, Department of Ophthalmology, University of North Carolina

Joshua P. Vrabec, M.D.Best Doctors in America

Sara Weidmayer, O.D.Admittance Committee, American Academy of Optometry

Jennifer S. Weizer, M.D.Best Doctors in America

Kwoon Y. Wong, Ph.D.Editorial Board, Current Eye ResearchGrant Reviewer, Velux FoundationsSpecial Emphasis Panel, Molecular and Cellular Substrates of Complex Brain Disorders [ZRG1 MDCN-P 57], National Institutes of HealthSpecial Emphasis Panel, Neurobiology of Visual Perception and Decision Making [ZRG1 IFCN-Q 02]], National Institutes of Health

Maria A. Woodward, M.D.Medical Director, Eversight MichiganAchievement Award, American Academy of Ophthalmology

Dongli Yang, M.D., Ph.D. Editorial Board, Austin Journal of Clinical Ophthalmology

David N. Zacks, M.D., Ph.D.Best Doctors in AmericaAchievement Award, American Academy of Ophthalmology

UNIVERSITY OF MICHIGAN AWARDS

David A. Antonetti, Ph.D B-EYE Challenge Award, University of Michigan Biointerfaces Institute

Cagri G. Besirli, M.D., Ph.D. University of Michigan Coulter Translational Research Program Award University of Michigan Translational Research and Commercialization for Life Sciences Program Kickstart Award

Brenda L. Bohnsack, M.D., Ph.D. Helmut F. Stern Career Development Professor of Ophthalmology and Visual Sciences

Hakan Demirci, M.D. B-EYE Challenge Award, University of Michigan Biointerfaces Institute

Thomas W. Gardner, M.D., M.S. Senior Scholar at the University of Michigan A. Alfred Taubman Medical Research Institute

K. Thiran Jayasundera, M.D. University of Michigan Translational Research and Commercialization for Life Sciences Program Award

Shahzad I. Mian, M.D.Gilbert Whitaker Fund for the Improvement of Teaching, University of Michigan Center for Research on Learning and Teaching

Paula Anne Newman-Casey, M.D., M.S.Community Service Award, University of Michigan Medical School

Howard R. Petty, Ph.D.University of Michigan Translational Research and Commercialization for Life Sciences Program Award

Rajesh C. Rao, M.D. Leslie H. and Abigail S. Wexner Emerging Scholar at the University of Michigan A. Alfred Taubman Medical Research Institute University of Michigan Biointerfaces Institute Award

Joshua D. Stein, M.D., M.S. Edward T. and Ellen K. Dryer Career Development Professor in Ophthalmology and Visual Sciences

Alan Sugar, M.D.League of Clinical Excellence, University of Michigan Medical School

Maria A. Woodward, M.D. Project Award, University of Michigan Health System Fostering Innovations Grants (FIGS) Program

FACULTY HONORS AND RECOGNITION JULY 1, 2014 — SEPTEMBER 30, 2015

34

Airik R, Slaats GG, Guo Z, Weiss AC, Khan N, Ghosh A, Hurd TW, Bekker-Jensen S, Schroder JM, Elledge SJ, Andersen JS, Kispert A, Castelli M, Boletta A, Giles RH, Hildebrandt F. Renal-retinal ciliopathy gene Sdccag8 regu-lates DNA damage response signaling. J Am Soc Nephrol. 2014 Nov;25(11):2573-83.

Alapati AN, Goetz K, Suk J, Navani M, Al-Tarouti A, Jayasundera KT, Lee P, Tumminia SJ, Ayyagari R. Molecular diagnostic testing by eyeGENE(R). Analysis of patients with he-reditary retinal dystrophy phenotype involving central vision loss. Invest Ophthalmol Vis Sci. 2014 Jul;55(9):5510-21.

Apkarian AO, Hervey-Jumper SL, Trobe JD. Cerebrospinal fluid leak presenting as oculor-rhea after blunt orbitocranial tauma. J Neur-oophthalmol. 2014 Sep;34(3):271-3.

Argento A, Kim W, Rozsa FW, DeBolt KL, Zikanova S, Richards JR. Shear behavior of bovine scleral tissue. J Biomech Eng. 2014 Jul;136(7).

Arora KS, Robin AL, Corcoran KJ, Corcoran SL, Ramulu PY. Use of various glaucoma surger-ies and procedures in Medicare beneficiaries from 1994 to 2012. Ophthalmology. 2015 Aug;122(8):1615-24.

Atkins SJ, Lentz SI, Fernando R, Smith TJ. Disrupted TSH receptor expression in female mouse lung fibroblasts alters subcellular IGF-1 receptor distribution. Endocrinology. 2015 Sep 21. [Epub ahead of print]

Bailey JN...Lichter PR...Moroi SE, Richards

JE, et al. Hypothesis-independent pathway analysis implicates GABA and Acetyl-CoA me-tabolism in primary open-angle glaucoma and normal-pressure glaucoma. Hum Genet. 2014 Oct;133(10):1319-30.

Bainbridge JW...Thompson DA...Ali RR, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med. 2015 May;372(20):1887-97.

Bansal S, Balakrishnan SA, Blachley T, Weizer

JS, Lee PP, Stein JD. Subsequent receipt of interventions for glaucoma among a nation-wide sample of patients who underwent laser peripheral iridotomy. Am J Ophthalmol. 2015 Aug;160(2):275-82.

Bashshur RL, Shannon GW, Smith BR, Woodward MA. The empirical evidence for the telemedicine intervention in diabetes management. Telemed J E Health. 2015 May;21(5):321-54.

Bavinger JC, DeLoss K, Mian SI. Scleral lens use in dry eye syndrome. Curr Opin Ophthal-mol. 2015 Jul;26(4):319-24.

Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, von Budingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015 May;2(3):e104.

Boss JD, Shah CT, Elner VM, Hassan AS. Assessment of office-based practice patterns on protective eyewear counseling for patients with monocular vision. Ophthal Plast Reconstr Surg. 2015 Sep-Oct;31(5):361-3.

Boyer DS, Goldbaum M, Leys AM, Starita C, Study Group: Johnson MW. Effect of pegap-tanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. Br J Ophthal-mol. 2014 Nov;98(11):1543-6.

Boynton GE, Raoof D, Niziol LM, Hussain M, Mian SI. Prospective randomized trial compar-ing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-a 0.05% for treat-ment of dry eye syndrome following hemato-poietic stem cell transplantation. Cornea. 2015 Jul;34(7):725-32.

Boynton GE, Stem MS, Kwark L, Jackson GR, Farsiu S, Gardner TW. Multimodal characterization of proliferative diabetic retinopathy reveals alterations in outer retinal function and structure. Ophthalmology. 2015 May;122(5):957-67.

Boynton GE, Woodward MA. Evolving tech-niques in corneal transplantation. Curr Surg Rep. 2015 Feb;3(2).

Boynton GE, Woodward MA. Eye-bank preparation of endothelial tissue. Curr Opin Ophthalmol. 2014 Jul;25(4):319-24.

Breker DA, Little AA, Trobe JD. Autoim-mune acquired rippling muscle disease and myasthenia gravis. J Neuroophthalmol. 2014 Mar;35(1):98-9.

Breker DA, Stacey AW, Srinivasan A, Bursztyn LL, Trobe JD, Johnson MW. Vision loss caused by retinal and lateral geniculate nucleus infarc-tion in H1N1 influenza. J Neuroophthalmol. 2015 Sep;35(3):265-9.

Briceño CA, Zhang-Nunes SX, Massry GG. Minimally invasive surgical adjuncts to upper blepharoplasty. Facial Plast Surg Clin North Am. 2015 May;23(2):137-51.

Brown JC, Goldstein JE, Chan TL, Massof R, Ramulu P, Low Vision Research Network Study Group: Day SH, Wicker DM. Characterizing functional complaints in patients seeking out-patient low-vision services in the United States. Ophthalmology. 2014 Aug;121(8):1655-62 e1651.

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

35

Chan TL, Perlmutter MS, Andrews M, Sun-ness JS, Goldstein JE, Massof RW, Low Vision Research Network Study Group: Day SH, Wicker DM. Equating visual function scales to facilitate reporting of medicare functional g-code severity/complexity modifiers for low-vision patients. Arch Phys Med Rehabil. 2015 Jul 9. [Epub ahead of print]

Chaudhary N, Griauzde J, Gemmete JJ, Pandey AS, Trobe JD. Issues in the diagnosis and management of the papilledema shunt. J Neuroophthalmol. 2014 Sep;34(3):259-63.

Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ, Douglas RS. Tepro-tumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014 Sep;99(9):E1635-40.

Chen H, Shan SJ, Mester T, Wei YH, Douglas

RS. TSH-mediated TNFalpha production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist. PLoS One. 2015 June;10(6):e0130322.

Chou CM, Nelson C, Tarlé SA, Pribila JT, Bardakjian T, Woods S, Schneider A, Glaser T. Biochemical basis for dominant inheritance, variable penetrance, and maternal effects in RBP4 congenital eye disease. Cell. 2015 Apr 23;161(3):634-46.

Choudhry N, Rao RC. Enhanced depth imag-ing features of a choroidal macrovessel. Retin Cases Brief Rep. 2015 May 29. [Epub ahead of print]

Choudhry N, Rao RC. Multimodal ultrawide-field imaging features in Waardenburg syndrome. Ophthalmic Surg Lasers Imaging Retina. 2015 Jun;46(6):670-3.

Coit P, De Lott LB, Nan B, Elner VM, Sawalha AH. DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis. Ann Rheum Dis. 2015 Jun 2. [Epub ahead of print]

Cornblath WT. Diplopia due to ocular motor cranial neuropathies. Continuum (Minneap Minn). 2014 Aug;20(4):966-80.

Daniel E, Quinn GE, Hildebrand PL, Ells A, Hubbard GB, 3rd, Capone A, Jr., Martin ER, Ostroff CP, Smith E, Pistilli M, Ying GS, e-ROP Cooperative Group: Musch DC. Validated system for centralized grading of retinopathy of prematurity: telemedicine ap-proaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study. JAMA Ophthal-mol. Jun 2015;133(6):675-82.

Davis RL, Eiden SB, Bennett ES, Koffler B, Wohl L, Lipson M. Stabilizing myopia by accelerating reshaping technique (SMART)-study three year outcomes and overview. Adv Ophthalmol Vis Syst. 2015 Apr;2(3):00046.

De la Parra-Colin PD, Barrientos-Gutierrez T, Mian SI. Axial length's role in intraocular lens power calculation error in x-linked megalocor-nea: a case-series analysis. Ophthalmic Genet. 2014;35(3):180-3.

DeLoss KS, Fatteh NH, Hood CT. Prosthetic replacement of the ocular surface ecosystem (PROSE) scleral device compared to kerato-plasty for the treatment of corneal ectasia. Am J Ophthalmol. 2014 Nov;158(5):974-82.

De Lott LB, Burke JF; Michigan Neuro-Ophthal-mology Research Consortium. Use of labora-tory markers in deciding whether to perform temporal artery biopsy. JAMA Ophthalmol. 2015 May;133(5):605-6.

de Melo Franco R, Kron-Gray MM, De la Parra-Colin P, He Y, Musch DC, Mian SI, Niziol L, Soong HK. Outcomes of cataract surgery in graft-versus-host disease. Cornea. 2015 May;34(5):506-11.

Demirci H, Cullen A, Sundstrom JM. Enhanced depth imaging optical coherence tomography of choroidal metastasis. Retina. 2014 Jul;34(7):1354-9.

Demirci H, Elner VM. Contemplating the diagnostic certainty of primary iris mucosa-associated lymphoid tissue Lymphoma-Reply. JAMA Ophthalmol. 2015 Aug 1. [Epub ahead of print]

Demirci H, Grant JS, Elner VM. Intralesional rituximab for primary iris lymphoma. JAMA Ophthalmol. 2015 Jan;133(1):104-5.

Demirci H, Saponara F, Khan A, Niziol LM, Lee C, Hayman JA, Comer G, Musch DC. Regression rate of posterior uveal melanomas following iodine-125 plaque radiotherapy. Middle East Afr J Ophthalmol. 2015 Jan-Mar;22(1):103-7.

Demirci H, Steen DW. Limitations in imaging common conjunctival and corneal pathologies with fourier-domain optical coherence tomog-raphy. Middle East Afr J Ophthalmol. 2014 Jul-Sep;21(3):220-4.

Demirci H, Worden F, Nelson CC, Elner VM, Kahana A. Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area. Ophthal Plast Reconstr Surg. 2015 Feb 11. [Epub ahead of print]

Dennis MD, Kimball SR, Fort PE, Jefferson LS. Regulated in development and DNA damage 1 is necessary for hyperglycemia-induced vascular endothelial growth factor expression in the retina of diabetic rodents. J Biol Chem. 2015 Feb 6;290(6):3865-74.

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

36

Dlouhy BJ, Awe O, Rao RC, Kirby PA, Hitchon PW. Autograft-derived spinal cord mass follow-ing olfactory mucosal cell transplantation in a spinal cord injury patient. J Neurosurg Spine. 2014 Oct;21(4):618-22.

Du Y, Cramer M, Lee CA, Tang J, Muthusamy

A, Antonetti DA, Jin H, Palczewski K, Kern TS. Adrenergic and serotonin receptors affect retinal superoxide generation in diabetic mice: relationship to capillary degeneration and permeability. FASEB J. 2015 May;29(5): 2194-204.

Dulle JE, Fort PE. Crystallins and neuroinflam-mation: the glial side of the story. Biochim Bio-phys Acta. 2015 Jun 3. [Epub ahead of print]

Duncan JL, Biswas P, Kozak I, Navani M, Syed R, Soudry S, Menghini M, Caruso RC, Jeffrey BG, Heckenlively JR, Reddy GB, Lee P, Roorda A, Ayyagari R. Ocular phenotype of a family with FAM161A-associated retinal degen-eration. Ophthalmic Genet. 2014:1-9.

Dunn SP, Gal RL, Kollman C, Raghinaru D, Dontchev M, Blanton CL, Holland EJ, Lass JH, Kenyon KR, Mannis MJ, Mian SI, Rapuano CJ, Stark WJ, Beck RW. Corneal graft rejec-tion 10 years after penetrating keratoplasty in the Cornea Donor Study. Cornea. 2014 Oct;33(10):1003-9.

Eisma JH, Dulle JE, Fort PE. Current knowledge on diabetic retinopathy from human donor tissues. World J Diabetes. 2015 Mar;6(2): 312-20.

Elam AR, Lee PP. Barriers to and suggestions on improving utilization of eye care in high-risk individuals: focus group results. Int Sch Res Notices. 2014 Oct, Article ID 527831.

Fernando R, Lu Y, Atkins SJ, Mester T, Branham K, Smith TJ. Expression of thyro-tropin receptor, thyroglobulin, sodium-iodide symporter, and thyroperoxidase by fibrocytes depends on AIRE. J Clin Endocrinol Metab. 2014 Jul;99(7):E1236-44.

Fort PE, Darche M, Sahel JA, Rendon A, Tadayoni R. Lack of dystrophin protein Dp71 results in progressive cataract formation due to loss of fiber cell organization. Molecular Vision. 2014 Nov;20:1480-90.

Fort PE, Losiewicz MK, Pennathur S, Jefferson LS, Kimball SR, Abcouwer SF, Gardner TW. mTORC1-independent reduction of retinal protein synthesis in type 1 diabetes. Diabetes. 2014 Sep;63(9):3077-90.

French CR, Seshadri S, Destefano AL, Fornage M, Arnold CR, Gage PJ, Skarie JM, Dobyns WB, Millen KJ, Liu T, Dietz W, Kume T, Hofker M, Emery DJ, Childs SJ, Waskiewicz AJ, Lehmann OJ. Mutation of FOXC1 and PITX2 induces cerebral small-vessel disease. J Clin Invest. 2014 Nov;124(11):4877-81.

Gage PJ, Kuang C, Zacharias AL. The home-odomain transcription factor PITX2 is required for specifying correct cell fates and establishing angiogenic privilege in the developing cornea. Dev Dyn. 2014 Nov;243(11):1391-400.

Galvin JA, LeBoyer RM, Michelotti M, Del Monte MA, Elner VM, Mian SI. Mosaic chromosome 18q partial deletion syndrome with bilateral full-thickness corneal disease: surgical intervention and histopathology. Ophthal Genetics. 2015 Mar;36(1):75-8.

Gardner TW, Abcouwer SF, Losiewicz MK, Fort PE. Phosphatase control of 4E-BP1 phos-phorylation state is central for glycolytic regula-tion of retinal protein synthesis. Am J Physiol Endocrinol Metab. 2015 Sep 15;309(6): E546-56.

Garnai SJ, Huyghe JR, Reed DM, Scott KM, Liebmann JM, Boehnke M, Richards JE, Ritch R, Pawar H. Congenital cataracts: de novo gene conversion event in CRYBB2. Molecular Vision. 2014 Nov;20:1579-93.

Ghodasra DH, Demirci H. Photodynamic therapy for choroidal metastasis. Am Ophthal-mol. 2015 Sep 30. [Epub ahead of print]

Goldstein JE, Jackson ML, Fox SM, Deremeik JT, Massof RW, Low Vision Research Network Study Group: Day SH, Wicker DM. Clinically meaningful rehabilitation outcomes of low vi-sion patients served by outpatient clinical cen-ters. JAMA Ophthalmol. 2015;133(7):762-9.

Gramage E, D'Cruz T, Taylor S, Thummel R, Hitchcock PF. Midkine-a protein localization in the developing and adult retina of the zebrafish and its function during photoreceptor regenera-tion. PLoS One. 2015 Mar;10(3):e0121789.

Grzegorski SJ, Chiari EF, Robbins A, Kish PE, Kahana A. Natural variability of Kozak se-quences correlates with function in a zebrafish model. PLoS One. 2014 Sep;9(9):e108475.

Gulati S, Andrews CA, Apkarian AO, Musch

DC, Lee PP, Stein JD. Effect of gestational age and birth weight on the risk of strabismus among premature infants. JAMA Pediatr. 2014 Sep;168(9):850-6.

Gupta C, Tanaka TS, Elner VM, Soong HK. Acute hydrops with corneal perforation in post-LASIK ectasia. Cornea. 2015 Jan;34(1): 99-100.

Haller T, Furr BA. Fresnel prism use among orthoptists. Am Orthopt J. 2014;64(1):71-5.

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

37

He Y, de Melo Franco R, Kron-Gray MM, Musch DC, Soong HK. Outcomes of cataract surgery in eyes with previous herpes zoster ophthalmicus. J Cataract Refract Surg. 2015 Apr;41(4):771-7.

Helm JE, Lavieri MS, Van Oyen MP, Stein JD, Musch DC. Dynamic forecasting and control al-gorithms of glaucoma progression for clinician decision support. Operations Research. 2015 Sep 9. [Epub ahead of print]

Hood CT, Bernard H. Conjunctival pigmenta-tion associated with long-term minocycline therapy. EyeNet. August 2014;18(8):2.

Hood CT, Sugar A. Subjective complaints after cataract surgery: common causes and manage-ment strategies. Curr Opin Ophthalmol. 2015 Jan;26(1):45-9.

Huang JT, Heckenlively JR, Jayasundera KT, Branham KE. The ophthalmic experience: un-anticipated primary findings in the era of next generation sequencing. J Genet Couns. 2014 Aug;23(4):588-93.

Hussain M, Shtein RM, Sugar A, Soong HK, Woodward MA, DeLoss K, Mian SI. Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease. Cornea. 2014 December;33(12):1245-51.

Hysi PG...Moroi SE, et al. Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. Nat Genet. 2014 Oct;46(10):1126-30.

Jackson GR, Gardner TW. Visual fields refine understanding of diabetic retinopathy progres-sion. Diabetes. 2014 Sep;63(9):2909-10.

Jain N, Johnson MW. Pathogenesis and treat-ment of maculopathy associated with cavitary optic disc anomalies. Am J Ophthalmol. 2014 Sep;158(3):423-35.

Jain N, Kozak JA, Niziol LM, Musch DC, Zacks DN. Vitrectomy alone in the man-agement of giant retinal tears. Ophthalmic Surg Lasers Imaging Retina. 2014 Sep-Oct;45(5):421-7.

Jayakody SA, Gonzalez-Cordero A, Ali RR, Pearson RA. Cellular strategies for retinal repair by photoreceptor replacement. Prog Retin Eye Res. 2015 May;46:31-66.

Johnson MW, Fahim AT, Rao RC. Acute ocriplasmin retinopathy. Retina. 2015 Jun;35(6):1055-8.

Katz DM, Trobe JD. Is there treatment for nonarteritic anterior ischemic optic neuropathy. Curr Opin Ophthalmol. 2015 Sep 11. [Epub ahead of print]

Kauh CY, Gupta S, Douglas RS, Elner VM, Nelson CC, Niziol LM, Kahana A. Compres-sive optic neuropathy and repeat orbital decompression: a case series. Ophthal Plast Reconstr Surg. 2015 Sep-Oct;31(5):385-90.

Khan M, Rao PK, Rao RC. Shimmering lights. JAMA Ophthalmol. 2014 Aug;132(8):1015-6.

Khan M, Walters LL, Li Q, Thomas DG, Miller JM, Zhang Q, Sciallis AP, Liu Y, Dlouhy BJ, Fort

PE, Archer SM, Demirci H, Dou Y, Rao RC. Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma. Lab Invest. 2015 Aug 17. [Epub ahead of print]

Khatib N, Polk T, Johnson MW. Diagnostic and therapeutic challenges. Retina. 2015 Jan;35(1):157-60.

Kiang L, Kahana A. Images in clinical medicine. Orbital varix. N Engl J Med. 2015 Feb;372(7):e9.

Kim DS, Korgavkar K, Zahid S, De Lott L, Prabhakar A, Foerster BR, Besirli CG. Vision loss after central retinal artery occlusion sec-ondary to orbital sarcoid mass. Ophthal Plast Reconstr Surg. 2014 Jul 28. [Epub ahead of print]

Kirtland KA, Saaddine JB, Geiss LS, Thompson TJ, Cotch MF, Lee PP. Geographic disparity of severe vision loss - United States, 2009-2013. MMWR Morb Mortal Wkly Rep. 2015 May;64(19):513-7.

Komaromy AM, Abrams KL, Heckenlively JR, Lundy SK, Maggs DJ, Leeth CM, MohanKumar PS, Petersen-Jones SM, Serreze DV, van der Woerdt A. Sudden acquired retinal degenera-tion syndrome (SARDS) - a review and pro-posed strategies toward a better understanding of pathogenesis, early diagnosis, and therapy.Vet Ophthalmol. 2015 Jun 20. [Epub ahead of print]

Kommaraju KR, Moroi S, Demirci H. Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia. Cornea. 2014 Aug;33(8):873-4.

Kremer S...Smith TJ, et al. Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder. JAMA Neurol. 2015 Jul;72(7):815-22.

Kristensen B, Hegedus L, Lundy SK, Brimnes MK, Smith TJ, Nielsen CH. Characteriza-tion of regulatory B cells in Graves' disease and Hashimoto's thyroiditis. PLoS One. 2015 May;10(5):e0127949.

Kristensen B, Hegedus L, Madsen HO, Smith TJ, Nielsen CH. Altered balance be-tween self-reactive Th17 cells and Th10 cells and between full-length FOXP3 and FOXP3 splice variants in Hashimoto's thyroiditis. Clin Exp Immunol. 2015 Apr;180(1):58-69.

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

38

Lagina A. Don't forget contact lenses in ocular rosacea. Rev Optom. 2015 Apr;152(4):50.

Lagina AL. Soft contact lens optimizes visual goals for a patient with keratoectasia. Optom Vis Sci. 2015 Sep 18. [Epub ahead or print]

Lass JH, Riddlesworth TD, Gal RL, Kollman C, Benetz BA, Price FW Jr, Sugar A, Terry MA, Soper M, Beck RW. Cornea Donor Study Research Group. The effect of donor diabetes history on graft failure and endothelial cell density 10 years after penetrating keratoplasty.Ophthalmology. 2015 Mar;122(3):448-56.

Lee BJ, Atkins S, Ginter A, Elner VM, Nelson

CC, Douglas RS. Increased CD40+ fibrocytes in patients with idiopathic orbital inflammation. Ophthal Plast Reconstr Surg. 2015 May-Jun;31(3):202-6.

Lee WB, Shtein RM, Kaufman SC, Deng SX, Rosenblatt MI. Boston keratoprosthesis: outcomes and complications: a report by the American Academy of Ophthalmology. Ophthalmology. 2015 Jul;122(7):1504-11.

Lertakyamanee P, Srinivasan A, De Lott LB, Trobe JD. Papilledema and vision loss caused by jugular paragangliomas. J Neuroophthal-mol. 2015 Jun 12. [Epub ahead of print]

Li B, Smith TJ. PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modu-lation by PTEN. J Clin Endocrinol Metab. 2014 Sept;99(9):3363-72.

Li Z... Richards JE, et al. A common variant near TGFBR3 is associated with primary open angle glaucoma. Hum Mol Genet. 2015 Jul;24(13):3880-92.

Lichter PR. Implications of the sunshine act-revelations, loopholes, and impact. Ophthal-mology. 2015 Apr;122(4):653-5.

Lichter PR. Payment data and the "me" in Medicare. Ophthalmology. 2014 Oct;121(10):1849-51.

Lin HC, Stein JD, Nan B, Childers D, Newman-Casey PA, Thompson DA, Richards

JE. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthal-mol. 2015 Aug 1;133(8):915-23.

Lipson MJ. Axial length measurement: PalmScan versus IOLMaster. Eye Contact Lens. 2015 May;41(3):156-9.

Liu H, Tang J, Du Y, Lee CA, Golczak M, Muthusamy A, Antonetti DA, Veenstra AA, Amengual J, Von Lintig J, Palczewski K, Kern TS. Retinylamine benefits early dia-betic retinopathy in mice. J Biol Chem. 2015 Aug;290(35):21568-79.

Liu Y...Lichter PR, Moroi SE...Richards J, et al. DNA copy number variants of known glau-coma genes in relation to primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2014 Nov;55(12):8251-8.

Majmudar PA, Schallhorn SC, Cason JB, Donaldson KE, Kymionis GD, Shtein RM, Verity SM, Farjo AA. Mitomycin-C in corneal surface excimer laser ablation techniques: a report by the American Academy of Ophthalmology. Ophthalmology. 2015 Jun;122(6):1085-95.

Malta JB, Renesto AC, Moscovici BK, Soong

HK, Campos M. Stromal demarcation line induced by corneal cross-linking in eyes with keratoconus and nonkeratoconic asymmetric to-pography. Cornea. 2015 Feb;34(2):199-203.

Marcet MM, Shtein RM, Bradley EA, Deng SX, Meyer DR, Bilyk JR, Yen MT, Lee WB, Mawn LA. Safety and efficacy of lacrimal drainage system plugs for dry eye syndrome: a report by the American Academy Of Ophthalmology. Ophthalmology. 2015 Aug;122(8):1681-7.

Marshall J, Wong KY, Rupasinghe CN, Tiwari R, Zhao X, Berberoglu ED, Sinkler C, Liu J, Lee I, Parang K, Spaller MR, Huttemann M, Goebel DJ. Inhibition of n-methyl-d-aspartate-induced retinal neuronal death by polyarginine pep-tides is linked to the attenuation of stress-in-duced hyperpolarization of the inner mitochon-drial membrane potential. J Biol Chem. 2015 Sep 4;290(36):22030-48.

McCartney AJ, Zolov SN, Kauffman EJ, Zhang Y, Strunk BS, Weisman LS, Sutton MA. Activity-dependent PI(3,5)P2 synthesis controls AMPA receptor trafficking during synaptic depression. Proc Natl Acad Sci USA. 2014 Nov;111(45):E4896-905.

McCoy AN, Kim DS, Gillespie E, Atkins S, Smith TJ, Douglas RS. Rituximab (Rituxan(R)) therapy for severe thyroid associated oph-thalmopathy diminishes IGF-1R T cells. J Clin Endocrinol Metab. 2014 Jul;99(7):E1294-9.

Melamed E...Smith TJ, et al. Update on bio-markers in neuromyelitis optica. Neurol Neuro-immunol Neuroinflamm. Aug 2015;2(4):e134.

Mian SI. Evaporative dry eye disease: promis-ing new approaches for diagnosis and treat-ment [Editorial]. Curr Opin Ophthalmol. 2015 Jul;26(4):288.

Mian SI. Evolution of a revolution in keratoplasty. Curr Opin Ophthalmol. 2014 Jul;25(4):298-9.

Michelotti MM, Gupta C, Hood CT. Persis-tent amine keratopathy secondary to indirect exposure to spray polyurethane foam insulation [Ophthalmic Image]. JAMA Ophthalmol. 2015 Jun;133(6):e1584.

Michelotti MM, Jain N, Johnson MW. Bilateral exudative retinal detachment in a diabetic patient with severe peripheral retinal ischemia. JAMA Ophthalmol. 2015 Jan;133(1):107-9.

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

39

Musch DC, Gillespie BW, Palmberg PF, Spaeth G, Niziol LM, Lichter PR. Visual field improve-ment in the collaborative initial glaucoma treatment study. Am J Ophthalmol. 2014 Jul;158(1):96-104.

Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER. Prognosis of ocular myasthe-nia gravis: retrospective multicenter analysis. Ophthalmology. 2015 Jul;122(7):1517-21.

Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology. 2015 Oct;122(10):2010-21.

Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, Lee PP. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthal-mology. 2015 July;122(7):1308-16.

Newman-Casey PA, Shtein RM, Coleman AL, Herndon L, Lee PP. Why patients with glau-coma lose vision: the patient perspective. J Glaucoma. 2015 Aug 27. [Epub ahead of print]

Newman-Casey PA, Stem M, Talwar N, Musch DC, Besirli CG, Stein JD. Risk factors associated with developing branch retinal vein occlusion among enrollees in a United States managed care plan. Ophthalmology. 2014 Oct;121(10):1939-48.

Newman-Casey PA, Verkade AJ, Oren GA, Robin AL. Gaps in glaucoma care: a systemat-ic review of monoscopic disc photos to screen for glaucoma. Exp Rev Ophthalmol. 2014 Dec;9(6):467-74.

Nika M, Blachley TS, Edwards P, Lee PP, Stein JD. Regular examinations for toxic macu-lopathy in long-term chloroquine or hydroxy-chloroquine users. JAMA Ophthalmol. 2014 Oct;132(10):1199-208.

Nika M, Kalyani PS, Jayasundera KT, Comer GM. Pathogenesis of persistent placoid maculopathy: a multimodal imaging analysis. Retina. 2015 Aug;35(8):1531-9.

Novack GD, Robin AL. Ocular pharmacology. J Clin Pharmacol. Sep 2015. [Epub ahead of print]

Ober MD, Freund KB, Shah M, Ahmed S, Mahmoud TH, Aaberg TM, Jr., Zacks DN, Gao H, Mukkamala K, Desai U, Packo KH, Yannuzzi LA. Stellate nonhereditary idiopathic foveomacular retinoschisis. Ophthalmology. 2014 Jul;121(7):1406-13.

Oliver V, Jaffe AE, Song J, Wang G, Zhang P, Branham KE, Swaroop A, Eberhart CG, Zack DJ, Qian J, Merbs SL. Differential DNA methylation identified in the blood and retina of AMD patients. Epigenetics. 2015 Aug;10(8):698-707.

Pack W, Hill DD, Wong KY. Melatonin modu-lates M4-type ganglion-cell photoreceptors. Neuroscience. 2015 Sep;303:178-88.

Padhi TR, Besirli CG. Re: Lepore et al.: Intra-vitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings (Letter). Ophthalmology. 2015;122(8):e47-48.

Patane PS, Krummenacher TK, Rao RC. Val-salva hemorrhagic retinopathy presenting as a rare cause of impaired vision after a general anesthetic-a case report and review of the lit-erature. J Clin Anesth. 2015 Jun;27(4):341-6.

Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol. 2015 Aug 10. [Epub ahead of print]

Ple-Plakon PA, Shtein RM. Trends in corneal transplantation: indications and techniques. Curr Opin Ophthalmol. 2014 Jul;25(4):300-5.

Prabhu SS, Shtein RM, Michelotti MM, Cooney TM. Topical cyclosporine A 0.05% for recurrent anterior uveitis. Br J Ophthalmol. 2015 Aug 18. [Epub ahead of print]

Rajaii F, McCoy AN, Smith TJ. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside. Expert Rev Ophthalmol. 2014 Jun;9(3):227-34.

Rao P, Shah AR, Michelotti MM, Ander-son B, Abbey AM, Jain N, Stec L, Lowe L, Johnson MW, Williams GA. Bilateral acute endophthalmitis associated with munchau-sen syndrome. Retin Cases Brief Rep. 2015 Spring;9(2):177-80.

Rao RC, Ballard TN, Chen TC. Iris heterochro-mia and unilateral eyelash hypertrichosis. JAMA. 2015 May;313(19):1967-8.

Rao RC, Choudhry N. Cystoid macular edema associated with chemotherapy. CMAJ. 2015 Aug 4. [Epub ahead of print]

Rao RC, Choudhry N. Enhanced depth imag-ing spectral-domain optical coherence tomog-raphy findings in choroidal neurofibromatosis. Ophthalmic Surg Lasers Imaging Retina. 2014 Sept-Oct;45(5):466-8.

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

40

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

Rao RC, Cohen SR, Mian SI. Silicone oil retention sutures for retinal detachment repair following traumatic aniridia, aphakia, and ruptured globe. JAMA Ophthalmol. Sep 10 2015;133(9):e151433.

Rao RC, Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015 Jun;15(6):334-46.

Rao RC, Elner VM, Demirci H. A red and swollen eyelid. Breast carcinoma metastasis to left lacrimal gland. JAMA Oncol. 2015 Jul;1(4):537-8.

Rao RC, Khan M, Badiyan SN, Harbour JW. Gene expression profiling and regression rate of irradiated uveal melanomas. Oph-thalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):333-7.

Ratnapriya R, Zhan X, Fariss RN, Branham KE...Heckenlively JR, et al. Rare and common variants in extracellular matrix gene Fibrillin 2 (FBN2) are associated with macular degeneration. Hum Mol Genet. 2014 Nov;23(21):5827-37.

Reifler AN, Chervenak AP, Dolikian ME, Benenati BA, Meyers BS, Demertzis ZD, Lynch AM, Li BY, Wachter RD, Abufarha FS, Dulka EA, Pack W, Zhao X, Wong KY. The rat retina has five types of ganglion-cell photoreceptors. Exp Eye Res. 2015 Jan;130:17-28.

Rootman DB, Kim MJ, Aldave AJ, Douglas R, Hwang C, Goldberg R. Ocular surface, fornix, and eyelid rehabilitation in Boston type I kera-toprosthesis patients with mucous membrane disease. Ophthal Plast Reconstr Surg. 2015 Jan-Feb;31(1):43-9.

Saera-Vila A, Kasprick DS, Junttila TL, Grzegorski SJ, Louie KW, Chiari EF, Kish PE, Kahana A. Myocyte dedifferentiation drives extraocular muscle regeneration in adult zebrafish. Invest Ophthalmol Vis Sci. Jul 1 2015;56(8):4977-93.

Saera-Vila A, Kish PE, Kahana A. Automated scalable heat shock modification for standard aquatic housing systems. Zebrafish. 2015 Aug;12(4):312-4.

Sand D, Amin S, Sugar A. April consulta-tion #2. J Cataract Refract Surg. 2015 Apr;41(4):896.

Savatovsky E, Mwanza JC, Budenz DL, Feuer WJ, Vandenbroucke R, Schiffman JC, Anderson DR, Study Group: Bergstrom TJ, Moroi SE, Pollack-Rundle CJ, Tehranisa MA. Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment. Ophthalmology. 2015 Jan;122(1):79-86.

Sayner R, Carpenter DM, Blalock SJ, Robin

AL, Muir KW, Hartnett ME, Giangiacomo AL, Tudor G, Sleath B. Accuracy of patient-report-ed adherence to glaucoma medications on a visual analog scale compared with electronic monitors. Clin Ther. 2015 Sep 1;37(9):1975-85.

Schell GJ, Lavieri MS, Helm JE, Liu X, Musch

DC, Van Oyen MP, Stein JD. Using filtered forecasting techniques to determine personal-ized monitoring schedules for patients with open-angle glaucoma. Ophthalmology. 2014 Aug;121(8):1539-46.

Scherer LD, Finan C, Simancek D, Finkelstein

JI, Tarini BA. Effect of "pink eye" label on parents' intent to use antibiotics and perceived contagiousness. Clin Pediatr (Phila). 2015 Aug 20. [Epub ahead of print]

Scott IU, Jackson GR, Quillen DA, Klein R, Liao J, Gardner TW. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in mild to moderate nonproliferative diabetic retinopathy: a ran-domized proof-of-concept clinical trial. JAMA Ophthalmol. 2014 Sep;132(9):1137-42.

Sealy-Jefferson S, Vickers J, Elam A, Wilson MR. Racial and ethnic health disparities and the affordable care act: a status update. J Racial Ethn Health Disparities. 2015 Jul. [Epub ahead of print].

Shelby SJ, Angadi PS, Zheng QD, Yao J, Jia L, Zacks DN. Hypoxia inducible factor 1alpha contributes to regulation of autophagy in retinal detachment. Exp Eye Res. 2015 Aug;137:84-93.

Shelby SJ, Feathers KL, Ganios AM, Jia L, Miller JM, Thompson DA. MERTK signaling in the retinal pigment epithelium regulates the tyrosine phosphorylation of GDP dissociation inhibitor alpha from the GDI/CHM family of RAB GTPase effectors. Exp Eye Res. 2015 Aug 15;140:28-40.

Singh RK, Mallela RK, Cornuet PK, Reifler AN, Chervenak AP, West MD, Wong KY, Nasonkin IO. Characterization of three-dimensional reti-nal tissue derived from human embryonic stem cells in adherent monolayer cultures. Stem Cells Dev. 2015 Sep 10. [Epub ahead of print]

Sleath B, Blalock SJ, Carpenter DM, Sayner R, Muir KW, Slota C, Lawrence SD, Giangiacomo AL, Hartnett ME, Tudor G, Goldsmith JA, Robin AL. Ophthalmologist-patient com-munication, self-efficacy, and glaucoma medication adherence. Ophthalmology. 2014 Apr;122(4):748-54.

41

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

Sleath B, Carpenter DM, Blalock SJ, Sayner R, Muir KW, Slota C, Giangiacomo AL, Hartnett ME, Tudor G, Robin AL. Applying the resourc-es and supports in self-management framework to examine ophthalmologist-patient communi-cation and glaucoma medication adherence. Health Educ Res. Oct 2015;30(5):693-705.

Slota C, Sayner R, Vitko M, Carpenter DM, Blalock SJ, Robin AL, Muir KW, Hartnett ME, Sleath B. Glaucoma patient expression of medi-cation problems and nonadherence. Optom Vis Sci. 2015 Oct;92(5):537-43.

Smith TA, Cornblath WT. Alternating superior and inferior oblique myokymia. JAMA Ophthal-mol. 2014 Jul;132(7):898-9.

Smith TJ. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nat Rev Endocrinol. 2015 Mar;11(3):171-81.

Springelkamp H...Richards JE, Musch DC, Moroi SE, Lichter PR, et al. Meta-analysis of genome-wide association studies identi-fies novel loci that influence cupping and the glaucomatous process. Nat Commun. 2014 Sep;5:4883.

Springelkamp H...Richards JE, Moroi SE, Lichter PR, et al. Meta-analysis of genome-wide association studies identifies novel loci associated with optic disc morphology. Genet Epidemiol. 2015 Mar;39(3):207-16.

Srinivasan PP, Kim LA, Mettu PS, Cousins SW, Comer GM, Izatt JA, Farsiu S. Fully automated detection of diabetic macular edema and dry age-related macular degeneration from optical coherence tomography images. Biomed Opt Express. 2014 Sep;5(10):3568-77.

Stacey AW, Sozener CB, Besirli CG. Hyperten-sive emergency presenting as blurry vision in a patient with hypertensive chorioretinopathy. Int J Emerg Med. 2015 Apr;8:13.

Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, Smith TJ, Douglas R. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 2015 Mar;133(3):290-6.

Stein JD, Shekhawat N, Talwar N, Balkrishnan R. Impact of the introduction of generic Latano-prost on glaucoma mediation adherence. Ophthalmology. 2015 Apr;122(4):738-47.

Stein JD, Talwar N, Kang JH, Okereke OI, Wiggs JL, Pasquale LR. Bupropion use and risk of open-angle glaucoma among enrollees in a large U.S. managed care network. PLoS One. 2015 Apr;10(4):e0123682.

Stem MS, Fahim A, Trobe JD, Parmar HA, Ibrahim M. Lateral geniculate lesions causing reversible blindness in a pre-eclamptic patient with a variant of posterior reversible encepha-lopathy syndrome. J Neuroophthalmol. 2014 Dec;34(4):372-6.

Stem MS, Hood CT. Salzmann nodular degen-eration associated with epithelial ingrowth af-ter LASIK treated with superficial keratectomy. BMJ Case Rep. 2015 Jan;2015.

Stem MS, Webster LS, Mian SI. Epithelial ingrowth as a cause of pseudohypopyon after descemet stripping automated endothe-lial keratoplasty. JAMA Ophthalmol. 2015 Apr;133(4):e144538.

Subramanian B, Anand M, Khan N, Khanna H. Loss of Raf-1 Kinase Inhibitory Protein (RKIP) delays early-onset severe retinal ciliopathy in Cep290rd16 mouse. Invest Ophthalmol Vis Sci. 2014 Aug;55(9):5788-94.

Sugar A. The importance of corneal endothe-lial cell survival after endothelial keratoplasty. JAMA Ophthalmol. Sep 2015:e1-2.

Sugar A, Gal RL, Kollman C, Raghinaru D, Dontchev M, Croasdale CR, Feder RS, Holland EJ, Lass JH, Macy JI, Mannis MJ, Smith PW, Soukiasian SH, Beck RW. Factors associated with corneal graft survival in the cornea donor study. JAMA Ophthalmol. 2015 Mar;133(3):246-54.

Sugar A, Sugar J, Schwab I, Perry H, de Luise V, Soong HK, Weiss J. Do it right the first time: advice for cornea authors. Cornea. 2014 Sep;33(9):879.

Suner IJ, Margolis J, Ruiz K, Tran I, Lee P. Direct medical costs and resource use for treating central and branch retinal vein oc-clusion in commercially insured working-age and Medicare populations. Retina. 2014 Nov;34(11):2250-8.

Tanaka TS, Elner VM, Demirci H. Solitary epibulbar neurofibroma in older adult patients. Cornea. 2015 Apr;34(4):475-8.

Tausif HN, Johnson L, Titus M, Mavin K, Chan-drasekaran N, Woodward MA, Shtein RM, Mian SI. Corneal donor tissue preparation for descemet's membrane endothelial keratoplasty. J Vis Exp. 2014 Sep;(91):51919.

Thompson DA, Ali RR, Banin E, Branham

KE, Flannery JG, Gamm DM, Hauswirth WW, Heckenlively JR, Iannaccone A, Jayasundera

KT, Khan NW, Molday RS, Pennesi ME, Reh TA, Weleber RG, Zacks DN. Advancing thera-peutic strategies for inherited retinal degenera-tion: recommendations from the Monaciano symposium. Invest Ophthalmol Vis Sci. 2015 Feb;56(2):918-31.

Undavia S, Briceño CA, Massry GG. Quanti-fied incision placement for postseptal approach transconjunctival blepharoplasty. Ophthal Plast Reconstr Surg. 2015 Apr 20. [Epub ahead of print]

42

FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015

Vadlamudi V, Gemmete JJ, Chaudhary N, Pandey AS, Kahana A. Transvenous sclero-therapy of a large symptomatic orbital venous varix using a microcatheter balloon and bleo-mycin. BMJ Case Rep. 2015 Jun 24.

Vadlamudi V, Gemmete JJ, Chaudhary N, Pandey AS, Kahana A. Transvenous sclero-therapy of a large symptomatic orbital venous varix using a microcatheter balloon and bleomycin. J Neurointerv Surg. 2015 Jun 29. [Epub ahead of print]

Vartanian GV, Li BY, Chervenak AP, Walch OJ, Pack W, Ala-Laurila P, Wong KY. Melatonin suppression by light in humans is more sensi-tive than previously reported. J Biol Rhythms. 2015 Aug;30(4):351-4.

Vartanian GV, Zhao X, Wong KY. Using flick-ering light to enhance nonimage-forming visual stimulation in humans. Invest Ophthalmol Vis Sci. 2015;56(8):4680-8.

Walch OJ, Zhang LS, Reifler AN, Dolikian ME, Forger DB, Wong KY. Characterizing and modeling the intrinsic light response of rat ganglion-cell photoreceptors. J Neurophysiol. 2015 Sep 23. [Epub ahead of print]

Wallace DJ, Chau FY, Santiago-Turla C, Hauser M, Challa P, Lee PP, Herndon LW, Allingham RR. Osteogenesis imperfecta and primary open angle glaucoma: genotypic analysis of a new phenotypic association. Mol Vis. 2014 Aug;20:1174-81.

Weidmayer S. Frontal mucocele with intracra-nial extension causing frontal lobe syndrome. Optom Vis Sci. 2015 Jun;92(6):e138-42.

Weidmayer S. Seeing red: how ocular rosa-cea impacts the cornea. Rev Optom. 2015 Apr;152(4):47-50.

Weidmayer SL, Bower AD. Pupillary respons-es can signal potentially serious problems. Prim Care Optom News. 2015 Feb;20(2):8-15.

Williams AL, Bohnsack BL. Neural crest de-rivatives in ocular development: discerning the eye of the storm. Birth Defects Res C Embryo Today. 2015 Jun;105(2):87-95.

Witkin AJ, Shah AR, Engstrom RE, Kron-Gray MM, Baumal CR, Johnson MW, Witkin DI, Leung J, Albini TA, Moshfeghi AA, Batlle IR, Sobrin L, Eliott D. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin. Ophthalmology. 2015 Jul;122(7):1438-51.

Wittes J, Musch DC. Should we test for geno-type in deciding on age-related eye disease study supplementation? Ophthalmology. 2015 Jan;122(1):3-5.

Wong SH, Plant GT, Cornblath W. Does treat-ment of ocular myasthenia gravis with early immunosuppressive therapy prevent second-arily generalization and should it be offered to all such patients? J Neuroophthalmol. 2015 Jul 24. [Epub ahead of print]

Woodward MA, Ple-Plakon P, Blachley T, Musch DC, Newman-Casey PA, De Lott LB, Lee PP. Eye care providers' attitudes towards tele-ophthalmology. Telemed J E Health. 2015 Apr;21(4):271-3.

Wu CY, Archer SM, Kahana A. "Tag-team" or-bital and strabismus surgeries with immediate reconstruction after tumor excision metastatic to the inferior rectus. Ophthal Plast Reconstr Surg. 2015 Feb 3. [Epub ahead of print]

Wu CY, Kahana A. Immediate reconstruction after combined embolization and resection of orbital arteriovenous malformation. Ophthal Plast Reconstr Surg. 2015 Apr 20. [Epub ahead of print]

Wu CY, Kahana A. Stereotactic navigation with a registration mask in orbital decompres-sion surgery: preliminary results. Ophthal Plast Reconstr Surg. 2015 Feb 11. [Epub ahead of print]

Wu RA, Grand P, Trobe JD. Diagnosis and management of ophthalmic emergencies in the hospital. Hosp Med Clin. 2014 Jul;3:e409-29.

Yao J, Jia L, Khan N, Lin C, Mitter SK, Boulton ME, Dunaief JL, Klionsky DJ, Guan JL, Thompson DA, Zacks DN. Deletion of autoph-agy inducer RB1CC1 results in degeneration of the retinal pigment epithelium. Autophagy. 2015 Jun;11(6):939-53.

Zhang L, Blachley TS, Weizer JS. Baerveldt 250 mm2 glaucoma drainage devices in eyes with preexisting scleral buckles. J Glaucoma. 2014 Aug 20. [Epub ahead of print]

Zhang S, Liang Y, Chen Y, Musch DC, Zhang C, Wang N. Utility analysis of vision-related quality of life in patients with glaucoma and different perceptions from ophthalmologists. J Glaucoma. 2015 Sep;24(7):508-14.

43

FACULTY NAME PROJECT TITLE SOURCE

S. Abcouwer, Ph.D. Bone Marrow Neuropathy Drives Diabetic Retinopathy; multi-PI NIH Regulation of Retinal Cell Death in Diabetes; multi-PI NIH Role of Interferon-gamma in the Retinal Neuroinflammatory ADA Control of Innate Inflammatory Responses in the Retina; multi-PI BrightFocus Foundation CCL2 Trap for Diabetic Retinopathy; multi-PI Novo Nordisk

D. Antonetti, Ph.D. Mechanisms of Retinal Vascular Permeability in Diabetes NIH The Retinal Microenvironment in Diabetic Retinopathy, NIH Subcontract with Northwestern University Novel Therapies to Inhibit Diabetic Retinopathy, NIH Subcontract with Case Western University Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes NIH Structural Studies of Tight Junction Proteins, NIH Subcontract with Pennsylvania State University Targeting aPKC as a Therapy for Diabetic Retinopathy JDRF CCL2 Trap for Diabetic Retinopathy; multi-PI Novo Nordisk Jules and Doris Stein RPB Professorship RPB

S. Archer, M.D. Ocular Toxicity of Combined Carboplatin and Etoposide Phosphate Intravitreal The Knights Templar Injection Therapy (IViT) for Retinoblastoma, Award for Stephen Smith, M.D. Foundation, Inc.

C. Besirli, M.D., Ph.D. Neuroprotection in Pediatric Retinal Detachment NIH Cryoanesthesia MEDC Testing of ONL Compounds in Retinal Cell Apoptosis Models ONL Therapeutics Career Development Award RPB

B. Bohnsack, M.D., Ph.D. Regulation of Ocular Neural Crest and Its Implications in Congenital Eye Diseases NIH Zebrafish Model of Primary Congenital Glaucoma: Understanding CYP1B1 Edward Mallinckrodt Jr. Foundation Regulation of Eye Development Career Development Award RPB

G. Comer, M.D., M.S. Treatment for Central-Involved Diabetic Macular Edema in Eyes, NIH/Clinical Trial Coordinating Center: Jaeb Center for Health Research Structural and Functional Relationships of the Retina in Diabetic Macular Edema JDRF A Natural History Study of Macular Telangiectasia—The MacTel Study LMRI/Clinical Trial A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic LMRI/Clinical Trial Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)

W. Cornblath, M.D. A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Efficacy Merck Research Labs & Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease

M. Del Monte, M.D. A 3-month, Multi-Center, Double-Masked Safety and Efficacy Study of Alcon Laboratories, Inc. Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patient Study of Binocular Computer Activities for Treatment of Amblyopia JAEB Center/NIH/Clinical Trial

EXTERNAL GRANTS AND FUNDING JULY 1, 2014 — SEPTEMBER 30, 2015

44

FACULTY NAME PROJECT TITLE SOURCE

R. Douglas, M.D., Ph.D. Role of CD40+ Fibrocytes in Thyroid-Associated Ophthalmopathy NIH A Multicenter, Double-Masked, Placebo-Controlled Efficacy and Safety Study River Vision LLC of RV001, an Insulin-like Growth Factor-1Receptor (IGF-1R) Antagonist Antibody (fully human), Administered Every 3 Weeks (Q3W) by Intravenous (IV) Infusion in Patients Suffering from Active Thyroid Eye Disease (TED) Lew R. Wasserman Merit Award RPB

S. Elner, M.D. Multicenter Uveitis Steroid Treatment (MUST) Trial, NIH/Clinical Trial Coordinating Center: Johns Hopkins University Macular Edema Treatment Trials Associated with MUST (META-MUST) NIH/Clinical Trial Intravitreal Injections of DE-109 for the Treatment of Active, Non-Infectious Uveitis Santen Pharmaceutical P. Fort, Ph.D., M.S. Progressive Impact of Diabetes on Retinal Neuroprotection by α-Crystallins NIH Characterization of Crystallin Proteins Expression in Human Retina: Effect Eversight of Diabetes Regulation of Crystallin Neuroprotective Function in the Retina During International Retinal Research Diabetes: Impact on Retinal Ganglion Cell Death Foundation P. Gage, Ph.D. Pitx 2: Molecular Mechanisms in Eye Development and Disease NIH An Inducible and Rapid Model of Glaucoma in Mice BrightFocus Foundation Analysis of Ocular Functions of CHD7 in Mouse Models of CHARGE CHARGE Syndrome Foundation, Inc. New Mouse Models of Human CHARGE Syndrome Eversight

T. Gardner, M.D., M.S. Metabolic Reprogramming in Diabetic Complications; multi-PI NIH Michigan Vision Clinician-Scientist Development Program; multi-PI NIH Regulation of Retinal Cell Death in Diabetes; multi-PI NIH Genes in Diabetic Retinopathy, Coordinating Center: Jaeb NIH/Clinical Trial Prompt Panretinal Photocoagulation (Protocol S), Coordinating Center: Jaeb NIH/Clinical Trial Clinical Research Training in Diabetic Macular Edema, Bayer HealthCare Award with Vinicius Monteiro de Castro, M.D., Ph.D. A Diabetic Retinopathy Risk of Progression Calculator Eversight Evaluation of Retinal Sensory Neuropathy JDRF Diabetic Complications Scientific Challenge Novo Nordisk Physician-Scientist Award RPB

J. Heckenlively, M.D. Investigation of Autoimmune Anti-Retinal Antibodies in Diabetes NIH Center for the Study of Retinal Degenerative Diseases FFB Clinical Evaluation of Individuals with X-linked Retinoschisis (XLRS) FFB and Applied Genetic Technologies Corp. A Phase II, Multiple-Site, Randomized, Placebo-Controlled Trial of Oral Valproic NNRI Acid for Retinitis Pigmentosa Retinitis Pigmentosa Natural History Study of Patients with the P23H Mutation The EMMES Corporation of the Rhodopsin Gene

EXTERNAL GRANTS AND FUNDING JULY 1, 2014 — SEPTEMBER 30, 2015

45

FACULTY NAME PROJECT TITLE SOURCE

P. Hitchcock, Ph.D. Neuronal Development, Injury and Repair in Retina NIH Vision Research Training Program NIH

B. Hughes, Ph.D. Core Center for Vision Research (five core modules) NIH Ion Conductances in the Retinal Pigment Epithelium NIH

K.T. Jayasundera, M.D. Novel Quantification Methods for Fundus Flavoprotein Fluorescence Eversight and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease EyeAnalyze: Automated Identification and Quantification of Changes in MEDC Retinal Diseases Post-Approval Study of the Argus II Retinal Prosthesis System Second Sight Medical Products, Inc

M. Johnson, M.D. Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients Genentech, Inc. with Geographic Atrophy Secondary to Age-Related Macular Degeneration

A. Kahana, M.D., Ph.D. A Zebrafish Model of Extraocular Muscle Regeneration NIH Investigating the Roles of Retinoic Acid and Thyroid Hormone in the Pathogenesis Alliance for Vision Research of Thyroid Eye Disease VISmodegib as Neo-adjuvant for ORBital and Periocular Basal Cell Carcinoma Genentech, Inc./Clinical Trial (VISORB) RPB Physician-Scientist Award

P. Lee, M.D., J.D. Michigan Vision Clinician-Scientist Development Program; multi-PI NIH Vision Health Initiative - IPA with CDC NIH Unrestricted Grant RPB Child Vision Care Fund W.K. Kellogg Foundation

M. Lipson, O.D. Overnight Corneal Reshaping - Quality of Life (OCRQL) Survey Instrument Bausch & Lomb, Inc.

S. Mian, M.D. Eye Bank Preparation of Donor Tissue for Descemet’s Membrane Eversight Endothelial Keratoplasty In vivo Assessment of a Novel Intraocular Pressure Transducer MEDC A Prospective, Multicenter, Post-Approval Study of Vision Care’s Implantable VisionCare Ophthalmic Miniature Telescope (by Dr. Isaac Lipshitz) in Patients with Bilateral Severe to Technologies, Ltd. Profound Central Vision Impairment Associated with End-Stage Age-Related Macular Degeneration

S. Moroi, M.D., Ph.D. Aqueous Humor Dynamic Components that Determine Intraocular NIH Pressure Variance The Efficacy and Safety of Bimatoprost SR in Patients with Open-Angle Glaucoma Allergan Pharmaceuticals, Inc./ or Ocular Hypertension Clinical Trial

D. Musch, Ph.D., M.P.H. Factors Predictive of Rapid Visual Field Loss in Early Glaucoma, NIH Subcontract with Washington University Statins to Prevent Glaucoma Trial (STOP Glaucoma Trial) Planning Grant; multi-PI NIH Assessing the Impact of Glaucoma and Its Treatment on the Person NIH

EXTERNAL GRANTS AND FUNDING JULY 1, 2014 — SEPTEMBER 30, 2015

46

P. Newman-Casey, M.D., M.S. Adherence to Glaucoma Medications Allergan Pharmaceuticals, Inc.

H. Petty, Ph.D. Nanoparticle Therapy in Cancer MEDC

D. Puro, M.D., Ph.D. Retinovascular Pathophysiology: Focus on Proliferative Retinopathy NIH

R. Rao, M.D. Sustaining Early-Born Retinal Neuron Potency from Stem Cells: RPB An Epigenetic Approach Targeting EZH2, a Histone Methyltransferase, as a Novel Therapy for The Knights Templar Human Retinoblastoma Foundation, Inc. J. Richards, Ph.D. Genetics of Homocycteine Metabolism in Glaucoma BrightFocus Foundation A Study of Ocular Aging Eversight Mechanics of Intraocular Pressure Increase Associated with NSF Genetic Factors; multi-PI

R. Shtein, M.D., M.S. Multinational, Collaborative Evaluation of Corneal Confocal Microscopy NIH as a Surrogate Endpoint for the Identification and Prediction of Diabetic Neuropathy in Type 1 Diabetes; multi-PI, Subcontract with Mount Sinai Hospital Assessment of Dry Eye Symptom Severity (DREAM study), NIH Subcontract with University of Pennsylvania Trends in Utilization of Endothelial and Penetrating Keratoplasty for Eversight Treatment of Corneal Endothelial Disease In vivo Effects of Antiglaucomatous Prostaglandin Therapy on Immune Cells, MEEI Epithelium, and Nerves of the Ocular Surface: A Laser in vivo Confocal Microscopy Study

T. Smith, M.D. Regulation of Retroocular Connective Tissue NIH UM-ACE: ACE Collaborative Project, NIH Subaccount with David A. Fox, M.D., Department of Internal Medicine, University of Michigan Physician-Scientist Award RPB

J. Stein, M.D., M.S. Statins to Prevent Glaucoma Trial (STOP Glaucoma Trial) NIH Collaboration on Cost-Effectiveness Analyses--DRCR Network, NIH Subcontract with JAEB Center for Health Research Workforce Assessment of Eye Care Providers American Academy of Ophthalmology Impact of Losartan Use on the Risk of Developing Open-Angle Glaucoma American Glaucoma Society A Dynamic, Personalized Glaucoma Monitoring Decision Support Glaucoma Research Foundation Model Enabled by an Extension of Kalman Filtering Theory Assessment of the Relation between Medications for Epilepsy and Risk of Harvard University Developing Open-Angle Glaucoma

EXTERNAL GRANTS AND FUNDING JULY 1, 2014 — SEPTEMBER 30, 2015

FACULTY NAME PROJECT TITLE SOURCE

47

EXTERNAL GRANTS AND FUNDING JULY 1, 2014 — SEPTEMBER 30, 2015

FACULTY NAME PROJECT TITLE SOURCE

J. Stein, M.D., M.S. (cont.) Do Patients with Vision Loss Use More Healthcare Services Lighthouse Guild Assessment of the Relation between Medications that Alter Innate Immunity MEEI and Glaucoma Physician-Scientist Award RPB The Epidemiology of Macular Holes and whether Use of Medication University of California Containing Estrogen Affect Development of Macular Holes San Francisco Are Medications Used to Treat HIV and Hepatitis Beneficial in Preventing University of Kentucky Macular Degeneration

A. Sugar, M.D. Corneal Preservation Time Study, Coordinating Center: Jaeb NIH/Clinical Trial

D. Thompson, Ph.D. Control of Innate Inflammatory Responses in the Retina; multi-PI BrightFocus Foundation Center for the Study of Retinal Degenerative Diseases FFB Gene-Replacement Therapy for XLRP Due to RPGR Mutations FFB Gene-Replacement Therapy for RDH12 Mutations RDH12 Fund for Sight

J. Trobe, M.D. Automated Diplopia Assessment System (ADAS); multi-PI, Medar Corporation/Michigan Award with Lindsey De Lott, M.D. Corporate Relations Network K. Wong, Ph.D. Physiology of Intrinsically Photosensitive Rentinal Ganglion Cells NIH Ameliorating the Condition of the Blind through Melanopsin Alliance for Vision Research Neural Circuits and Synapses for Early Visual Processing US Department of Defense-Army

M. Woodward, M.D. Telemedicine For Anterior Eye Diseases NIH

D. Zacks, M.D., Ph.D. Autophagy and Control of Photoreceptor Apoptosis NIH Autophagy and Control of Photoreceptor Cell Death in Autosomal Dominant Bayer HealthCare Retinitis Pigmentosa Center for the Study of Retinal Degenerative Diseases FFB Dysregulaton of RPE Autophagy and Age-related Macular Degeneration RPB

SOURCE ABBREVIATIONSADA ..... American Diabetes AssociationFFB ...... Foundation Fighting BlindnessJDRF ..... Juvenile Diabetes Research Foundation InternationalMEEI .... Massachusetts Eye and Ear InfirmaryMEDC ... Michigan Economic Development Corporation

NIH ...... National Institutes of HealthNNRI .... National Neurovision Research InstituteNSF ...... National Science FoundationRPB ...... Research to Prevent Blindness

W.K. KELLO

GG

EYE CEN

TER FAC

ULTY, FELLO

WS, A

ND

RESIDEN

TS 2015

Faculty of the Department of Ophthalmology and Visual Sciences

First row (left to right):Sejal Amin, M.D., Melisa Nika, M.D., Courtney Kauh, M.D., M.S., Paul Lichter, M.D., M.S., Michael Smith-Wheelock, M.D., H. Kaz Soong, M.D., Alan Sugar, M.D., Monte Del Monte, M.D., Paul Lee, M.D., J.D., Christine Nelson, M.D., Denise John, M.D., Mark Johnson, M.D., Shahzad Mian, M.D., Thomas Gardner, M.D., M.S., Donna Wicker, O.D., Dolly Padovani-Claudio, M.D., Ph.D., Shannon Joseph, M.D.

Second row (left to right):Joshua Stein, M.D., M.S., Matthew Manry, M.D., Rajesh Rao, M.D., Anjali Shah, M.D., Paula Anne Newman-Casey, M.D., M.S., Gale Oren, M.I.L.S., Kari Branham, M.S., Naheed Khan, Ph.D., Dongli Yang, M.D., Ph.D., Kwoon Wong, Ph.D., Patrice Fort, Ph.D., M.S., David Musch, Ph.D., M.P.H., Alon Kahana, M.D., Ph.D., César Briceño, M.D., Cagri Besirli, M.D., Ph.D., Stephen Smith, M.D., Grace Wang, M.D., Ph.D., Catherine Choi, M.D., Sophia Wang, M.D., Marina Eisenberg, M.D., Fatemeh Rajaii, M.D., Ph.D.

Third row (left to right): Karen Christopher, M.D., Stephen Odaibo, M.D., Hakan Demirci, M.D., Daniel Kasprick, M.D., Sara Weidmayer, O.D., Zvi Kresch, M.D., Cheng-mao Lin, Ph.D., Roni Shtein, M.D., M.S., Courtney Dewey, O.D., Elizabeth Du, M.D., Abigail Fahim, M.D., Ph.D., Wayne Cornblath, M.D., Amy Lagina, O.D., K. Thiran Jayasundera, M.D., Sherry Day, O.D., Lee Kiang, M.D., Ph.D., Neil Farbman, M.D., J.D., Steven Cohen, M.D.

Fourth row (left to right):Angela Elam, M.D., Krista Stewart, M.D., Daniel Albertus, M.D., Shivani Gupta, M.D., Donald Puro, M.D., Ph.D., Bradley Taylor, O.D., M.P.H., Christopher Gappy, M.D., Karen DeLoss, O.D., Susan Elner, M.D., Theresa Cooney, M.D., Joshua Vrabec, M.D., Steven Archer, M.D., Lindsey De Lott, M.D., Rebecca Wu, M.D., Ariane Kaplan, M.D., Monica Michelotti, M.D., Kevin Tozer, M.D., Devon Ghodasra, M.D.

Fifth row (left to right):Daniel Sand, M.D., Marius A. Tijunelis, M.D., M.B.A., Terry Smith, M.D., John Heckenlively, M.D., Paul Grenier, O.D., Steven Abcouwer, Ph.D., Terry Bergstrom, M.D., Gary Sandall, M.D., M.S., Bret Hughes, Ph.D., Philip Gage, Ph.D., Grant Comer, M.D., M.S., Jonathan Greene, M.D., Jerome Finkelstein, M.D., Helios Leung, O.D., Ph.D., Andrew Stacey, M.D., M.S., Maxwell Stem, M.D., David DeMill, M.D., Andrew Lewis, M.D., Kristopher Kowal, M.D.

For a complete listing of our faculty, visit: www.kellogg.umich.edu/about/faculty_bios.html

Executive Officers of the University of Michigan Health System Marschall S. Runge, M.D., Ph.D.Executive Vice President for Medical Affairs and Dean of the Medical School

David A. Spahlinger, M.D.Executive Vice Dean for Clinical Affairs and President of the Hospitals, Health Centers, and U-M Medical Group

T. Anthony Denton, J.D., M.H.A.Senior Vice President and Chief Operating Officer for the Hospitals, Health Centers, and U-M Medical Group

The Regents of the University of Michigan

Michael J. Behm, Mark J. Bernstein, Laurence B. Deitch, Shauna Ryder Diggs, Denise Ilitch, Andrea Fischer Newman, Andrew C. Richner, Katherine E. White, Mark S. Schlissel (ex officio)

Editor: Jonathan D. Trobe, M.D.

Writers: Aimee Bergquist, Barbara Sefton

Editorial Assistant: Lisa Burkhart

Design and Art Direction: David Murrel

Photographers: Eric Bronson, Daryl Marshke, Scott Soderberg, Austin Thomason, Michigan Photography; Amber Schultz, U-M Department of Ophthalmology and Visual Sciences

FOR PATIENT APPOINTMENTS, PLEASE CALL 734.763.8122

For additional copies, please contact us: University of Michigan Department of Ophthalmology and Visual SciencesW.K. Kellogg Eye Center1000 Wall StreetAnn Arbor, Michigan 48105

734.763.4660 • www.kellogg.umich.edu

All of us at the Kellogg Eye Center are

committed to improving lives through curing,

preventing, and treating eye disease.

Our guiding principles are teamwork, caring,

innovation, and integrity.

University of MichiganW.K. Kellogg Eye CenterDepartment of Ophthalmology and Visual Sciences1000 Wall StreetAnn Arbor, MI 48105

#10 OPHTHALMOLOGYIN THE NATION

2015 U.S. NEWS & WORLD REPORT’S “BEST HOSPITALS”

The University of Michigan Kellogg Eye Center is proud to be ranked #10 in the country by U.S. News & World Report for being among the nation’s best in providing outstanding care for the most complex eye conditions.

Kellogg has seen extraordinary growth in all aspects of patient care, research and education since the department was estab- lished in 1872. Every day, our clinicians, scientists, trainees and staff work together to shape the future of eye care and vision science. The Kellogg team is especially proud of these recent accomplishments:

• Kelloggretinalsurgeonsperformedthefirstfoursurgeries intheUnitedStatestoimplantanartificialretina,or “bioniceye,”sincetheFDAapprovedthedevicein2013.

• Kelloggscientistsreceived$14Minresearchfundingin FY2015,with$6.8McomingfromtheNationalInstitutes ofHealth(NIH).ThisranksKellogg#10inNIHfunding amongU.S.eyeinstitutions.

• Kelloggisoneofthetopeyecentersintheworldfortraining thenextgenerationofphysician-scientists.In2015,Doximity rankedKellogg’sresidencyprogram#8inreputationand #6inresearchoutput.

Kellogg Among Nation’s Best in Eye Care